DE69736331D1 - Immunstimulierende nukleinsaeuremolekuele - Google Patents

Immunstimulierende nukleinsaeuremolekuele

Info

Publication number
DE69736331D1
DE69736331D1 DE69736331T DE69736331T DE69736331D1 DE 69736331 D1 DE69736331 D1 DE 69736331D1 DE 69736331 T DE69736331 T DE 69736331T DE 69736331 T DE69736331 T DE 69736331T DE 69736331 D1 DE69736331 D1 DE 69736331D1
Authority
DE
Germany
Prior art keywords
nucleic acid
acid molecules
immunostimulatory oligonucleotide
bases
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69736331T
Other languages
English (en)
Other versions
DE69736331T2 (de
Inventor
M Krieg
N Kline
Dennis Klinman
Alfred D Steinberg
George Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
US Department of Health and Human Services
Original Assignee
University of Iowa Research Foundation UIRF
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24968901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69736331(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Iowa Research Foundation UIRF, US Department of Health and Human Services filed Critical University of Iowa Research Foundation UIRF
Publication of DE69736331D1 publication Critical patent/DE69736331D1/de
Application granted granted Critical
Publication of DE69736331T2 publication Critical patent/DE69736331T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69736331T 1996-10-30 1997-10-30 Immunstimulierende nukleinsaeuremolekuele Revoked DE69736331T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US738652 1996-10-30
US08/738,652 US6207646B1 (en) 1994-07-15 1996-10-30 Immunostimulatory nucleic acid molecules
PCT/US1997/019791 WO1998018810A1 (en) 1996-10-30 1997-10-30 Immunostimulatory nucleic acid molecules

Publications (2)

Publication Number Publication Date
DE69736331D1 true DE69736331D1 (de) 2006-08-24
DE69736331T2 DE69736331T2 (de) 2007-08-09

Family

ID=24968901

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69736331T Revoked DE69736331T2 (de) 1996-10-30 1997-10-30 Immunstimulierende nukleinsaeuremolekuele

Country Status (14)

Country Link
US (32) US6207646B1 (de)
EP (5) EP1714969A3 (de)
JP (5) JP2001503267A (de)
KR (1) KR100689942B1 (de)
CN (2) CN101265285A (de)
AT (1) ATE332966T1 (de)
AU (3) AU5242498A (de)
CA (1) CA2270345C (de)
DE (1) DE69736331T2 (de)
DK (1) DK0948510T3 (de)
ES (2) ES2268736T3 (de)
NZ (1) NZ335397A (de)
PT (1) PT948510E (de)
WO (1) WO1998018810A1 (de)

Families Citing this family (834)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6498147B2 (en) * 1992-05-22 2002-12-24 The Scripps Research Institute Suppression of nuclear factor-κb dependent processes using oligonucleotides
CA2110946A1 (en) * 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
US20030109469A1 (en) * 1993-08-26 2003-06-12 Carson Dennis A. Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7034007B1 (en) * 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) * 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
EP0909323B1 (de) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Bakterioferritin aus helicobacter pylori
JP4359654B2 (ja) * 1996-01-30 2009-11-04 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
CA2268957C (en) 1996-10-25 2008-04-29 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of th2 mediated and related diseases
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
NZ337054A (en) * 1997-01-30 2001-03-30 Chiron Corp Microparticles PLA and PLG with adsorbed viral antigen to stimulate immune responses particularly for intracellular viruses such as HSV-1 or HSV-2, varicella zoster virus. epstein-barr virus or cytomegalovirus (CMV)
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
AU738513B2 (en) * 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1005368B1 (de) * 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6426334B1 (en) * 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20030104044A1 (en) * 1997-05-14 2003-06-05 Semple Sean C. Compositions for stimulating cytokine secretion and inducing an immune response
US6287591B1 (en) 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
EP1003531B1 (de) 1997-05-20 2007-08-22 Ottawa Health Research Institute Verfahren zur Herstellung von Nukleinsäurekonstrukten
EP1374894A3 (de) * 1997-06-06 2004-09-22 Dynavax Technologies Corporation Immunstimulierende Oligonukleotide, Zusammensetzungen und Verwendungen davon
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6221882B1 (en) * 1997-07-03 2001-04-24 University Of Iowa Research Foundation Methods for inhibiting immunostimulatory DNA associated responses
AU2003203948B2 (en) * 1997-09-05 2005-12-22 The Regents Of The University Of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
JP4663113B2 (ja) * 1997-09-05 2011-03-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
WO1999051259A2 (en) * 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU3884199A (en) * 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
NZ508650A (en) * 1998-05-14 2003-05-30 Coley Pharm Gmbh Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
DK1079824T3 (da) 1998-05-19 2011-11-21 Res Dev Foundation Triterpen-sammensætninger og fremgangsmåder til anvendelse deraf
DE69932717T2 (de) * 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
KR19990086271A (ko) * 1998-05-27 1999-12-15 손경식 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
EP1100807A1 (de) * 1998-07-27 2001-05-23 University Of Iowa Research Foundation Stereoisomere von cpg oligonukleotiden und verwandte verfahren
US7049302B1 (en) 1998-08-10 2006-05-23 Antigenics Inc. Compositions of CPG and saponin adjuvants and uses thereof
CA2343052A1 (en) * 1998-09-18 2000-03-30 Dynavax Technologies Corporation Methods of treating ige-associated disorders and compositions for use therein
AU6425999A (en) * 1998-10-09 2000-05-01 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
WO2000037067A2 (en) * 1998-12-22 2000-06-29 Panacea Pharmaceuticals, Llc Sensitizing agents for the treatment of skin lesions
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
ATE464907T1 (de) * 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
PT1154790E (pt) * 1999-02-26 2005-03-31 Chiron Srl Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
GB2348132B (en) * 1999-03-02 2004-08-04 Nedaa Abdul-Ghani Nasif Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
EP1176966B1 (de) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6562801B1 (en) 1999-04-15 2003-05-13 Board Of Regents, The University Of Texas System PpGpp and pppGpp as immunomodulatory agents
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
PL203951B1 (pl) * 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
CA2370708A1 (en) * 1999-04-20 2000-10-26 Smithkline Beecham Biologicals S.A. Vaccine comprising rsv antigen and cpg oligonucleotide
ATE306938T1 (de) * 1999-06-29 2005-11-15 Glaxosmithkline Biolog Sa Verwendung von cpg als adjuvans für hivimpstoff
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
FR2795963A1 (fr) * 1999-07-08 2001-01-12 Pasteur Merieux Serums Vacc Polynucleotide immunostimulant
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
WO2001012804A2 (en) * 1999-08-13 2001-02-22 Hybridon, Inc. MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
EP1204425B1 (de) 1999-08-19 2009-01-07 Dynavax Technologies Corporation Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
AU780535B2 (en) * 1999-08-27 2005-03-24 Inex Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response
US20050249794A1 (en) * 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
AP2006003503A0 (en) * 1999-09-25 2006-02-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
EP1688147A1 (de) * 1999-09-27 2006-08-09 Coley Pharmaceutical Group, Inc. Verfahren mittels durch Nukleinsäuren induziertes immunstimulatorisches Interferon
EP1220684B2 (de) * 1999-09-27 2010-07-14 Coley Pharmaceutical Group, Inc. Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
ES2541830T3 (es) 1999-10-29 2015-07-27 Novartis Vaccines And Diagnositics S.R.L. Péptidos antigénicos de Neisseria
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
EP1322655B1 (de) * 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
AU3108001A (en) * 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
US6552006B2 (en) 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20030130217A1 (en) * 2000-02-23 2003-07-10 Eyal Raz Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US6613751B2 (en) 2000-02-23 2003-09-02 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
WO2001062092A1 (en) * 2000-02-25 2001-08-30 Thomas Jefferson University Formulations and methods for using the same to elicit an immune response
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
AU2001251407A1 (en) * 2000-04-07 2001-10-23 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
ES2238044T3 (es) * 2000-05-01 2005-08-16 Hybridon, Inc. Modulacion de la estimulacion inmunologica mediada por el oligonucleotido cpg mediante modificacion posicional de nucleosidos.
US6696064B2 (en) * 2000-06-20 2004-02-24 The United States Of America As Represented By The Department Of Health And Human Services Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy
US7767197B2 (en) 2000-06-22 2010-08-03 Endo Pharmaceuticals Colorado LLC Delivery vehicle composition and methods for delivering antigens and other drugs
AU7013401A (en) 2000-06-22 2002-01-02 Univ Iowa Res Found Methods for enhancing antibody-induced cell lysis and treating cancer
CA2410297C (en) * 2000-06-23 2011-03-15 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)
WO2002002172A1 (en) * 2000-06-30 2002-01-10 Univ Jefferson Dna palindrome - oligoguanylic acid compositions and uses thereof
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
JP2005503320A (ja) * 2000-08-25 2005-02-03 イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド ＣｐＧ−含有ポリヌクレオチドで自己免疫疾患を処置または防止する方法
WO2002022809A2 (en) * 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
CA2423487C (en) * 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
CA2425303A1 (en) 2000-10-27 2002-05-02 John Telford Nucleic acids and proteins from streptococcus groups a & b
JP2008531580A (ja) * 2000-12-08 2008-08-14 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾因子の標的化送達のための組成物および方法
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
DE60142410D1 (de) * 2000-12-27 2010-07-29 Dynavax Tech Corp Immunomodulatorische polynukleotide und verfahren zur deren verwendung
KR20030070101A (ko) * 2001-01-12 2003-08-27 아마토 세이야쿠 가부시키가이샤 미생물 감염 방지제
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
EP1355661A2 (de) * 2001-01-31 2003-10-29 Mologen Forschungs-, Entwicklungs- und Vertriebs GmbH Tumorvakzine
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
CA2443493A1 (en) * 2001-04-13 2002-10-24 Wyeth Surface proteins of streptococcus pyogenes
US20070128229A1 (en) * 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
EP1572868A4 (de) 2001-04-16 2007-04-04 Wyeth Corp Neue, polypeptidantigene codierende offene leseraster aus streptococcus pneumoniae und verwendungen davon
US7034140B2 (en) * 2001-04-24 2006-04-25 E.I. Du Pont De Nemours And Company Genes involved in isoprenoid compound production
CA2448031A1 (en) 2001-05-21 2002-11-28 Intercell Ag Method for stabilising of nucleic acids
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
CN100334228C (zh) 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
CN1931365A (zh) * 2001-06-29 2007-03-21 希龙公司 Hcv e1e2疫苗组合物
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003012061A2 (en) * 2001-08-01 2003-02-13 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
JP2005518343A (ja) * 2001-08-03 2005-06-23 メダレックス， インク． 新規なｐｇｃ−１イソフォームおよびその使用媒介型免疫治療を向上させるためのその使用
WO2003014316A2 (en) 2001-08-07 2003-02-20 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
SI1446162T1 (sl) * 2001-08-17 2009-04-30 Coley Pharm Gmbh Kombinacija zaporedja imunostimulatornih oligonukleotidov z izboljšano aktivnostjo
CN100488981C (zh) 2001-08-24 2009-05-20 维多利亚大学创新和发展公司 含有蛋白酶激活序列的气单胞菌溶素原及其应用
US20030133913A1 (en) * 2001-08-30 2003-07-17 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
BR0212366A (pt) * 2001-09-07 2004-07-27 Univ Boston Método e composição para tratar distúrbios associados com o complexo imune
EP2196217A1 (de) 2001-09-14 2010-06-16 Cytos Biotechnology AG Verpackung von immunstimulierenden Mitteln in virusähnischen Partikeln: Herstellungsverfahren und Verwendung
JP4360906B2 (ja) * 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
WO2003027313A2 (en) 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US7514415B2 (en) 2002-08-01 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
US20030119774A1 (en) * 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2461315A1 (en) * 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
CN100438908C (zh) * 2001-10-06 2008-12-03 梅瑞尔有限公司 CpG制剂及相关方法
DK1455593T3 (da) 2001-10-06 2013-08-26 Merial Ltd Fremgangsmåder og sammensætninger til fremme af vækst og medfødt immunitet hos unge dyr
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2002360278A1 (en) * 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US20030125292A1 (en) * 2001-11-07 2003-07-03 Sean Semple Mucoscal vaccine and methods for using the same
EP1441758A2 (de) * 2001-11-09 2004-08-04 MediGene Aktiengesellschaft Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
US7179798B2 (en) * 2001-11-16 2007-02-20 Russell R. Roby Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
DK1719511T3 (da) * 2001-11-16 2009-04-14 Coley Pharm Group Inc N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
JP2005519035A (ja) * 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
WO2003055514A1 (en) * 2001-12-21 2003-07-10 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
CA2474709A1 (en) * 2002-02-04 2003-08-14 Biomira, Inc. Immunostimulatory, covalently lipidated oligonucleotides
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP2572707A3 (de) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Mikropartikel mit adsorbierten polypeptidhaltigen Molekülen
JP2005518433A (ja) * 2002-02-22 2005-06-23 スリーエム イノベイティブ プロパティズ カンパニー Ｕｖｂ−誘導免疫抑制を軽減し治療する方法
US6923958B2 (en) * 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
EP2258712A3 (de) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
KR100981471B1 (ko) * 2002-03-15 2010-09-10 더 큐레이터스 오브 더 유니버시티 오브 미주리 효소 활성이 감소된 형별불능 헤모필러스 인플루엔자의ｐ4 변형 단백질
JP2005526778A (ja) * 2002-03-15 2005-09-08 アストラル，インコーポレイテッド 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
KR100456681B1 (ko) * 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
DE60335186D1 (de) * 2002-06-20 2011-01-13 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AU2003247880B2 (en) * 2002-07-03 2010-09-02 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AU2003255969A1 (en) * 2002-07-17 2004-02-02 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease
US20060270620A1 (en) * 2002-07-23 2006-11-30 University Of South Florida Method of Enhancing Therapeutic Effect of Nucleic Acids
CN1650012A (zh) 2002-07-24 2005-08-03 英特塞尔股份公司 来自致病病毒的备选阅读框所编码的抗原
AU2003299863B2 (en) 2002-08-15 2009-09-24 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7595303B1 (en) * 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
CA2484339A1 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
CN1694959B (zh) * 2002-09-13 2013-09-18 雷普利瑟公司 非序列互补的抗病毒寡核苷酸
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
WO2004031382A1 (ja) * 2002-10-02 2004-04-15 Mochida Pharmaceutical Co., Ltd. 新規なモノクローナル抗体の作製方法
US8043622B2 (en) 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
DK2351579T3 (en) 2002-10-11 2017-01-09 Novartis Vaccines And Diagnostics S R L Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages.
CA2503457A1 (en) * 2002-10-25 2004-05-06 University Of Connecticut Health Center Apparatus and method for immunotherapy of a cancer through controlled cell lysis
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
JP4976653B2 (ja) * 2002-11-01 2012-07-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス 免疫刺激性ＣｐＧオリゴヌクレオチドを用いてバイオテロ病原体による感染症を予防する方法
CA2504929C (en) * 2002-11-05 2014-07-22 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP2279746B1 (de) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Oberflächenproteine in neisseria meningitidis
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US7811813B2 (en) * 2002-11-21 2010-10-12 The Board Of Trustees Of The Leland Stanford Junior University Methods and immune modulatory nucleic acid compositions for preventing and treating disease
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003300919A1 (en) * 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
US20040213808A1 (en) * 2002-12-11 2004-10-28 Michael Lieberman Recombinant vaccine against flavivirus infection
CN100546998C (zh) 2002-12-23 2009-10-07 戴纳伐克斯技术股份有限公司 免疫刺激序列寡核苷酸和使用方法
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
JP2006516099A (ja) * 2002-12-23 2006-06-22 ダイナバックス テクノロジーズ コーポレイション 分枝状の免疫調節化合物及び該化合物の使用方法
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
EP2289546A3 (de) 2003-01-30 2011-03-30 Novartis Vaccines and Diagnostics S.r.l. Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
ES2385933T3 (es) 2003-02-20 2012-08-03 University Of Connecticut Health Center Métodos para la producción de complejos de moléculas antígenas de alfa (2) macroglobulina.
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
US7485432B2 (en) * 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
AU2004218349A1 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
CN100439386C (zh) * 2003-03-05 2008-12-03 长春华普生物技术有限公司 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸
MXPA05009694A (es) * 2003-03-13 2005-10-20 3M Innovative Properties Co Metodos para mejorar la calidad de la piel.
CA2518445A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US7704514B2 (en) 2003-03-24 2010-04-27 Intercell Ag Vaccines
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
CN1795274A (zh) * 2003-03-26 2006-06-28 多单元免疫治疗公司 诱导细胞死亡和/或凋亡的选定的rna基序
CA2517839A1 (en) 2003-03-26 2004-10-07 Martin F. Bachmann Melan-a peptide analogue-virus-like-particle conjugates
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US20040235770A1 (en) * 2003-04-02 2004-11-25 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
AU2004244962A1 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
JP2007525177A (ja) 2003-04-21 2007-09-06 アーケミックス コーポレイション 血小板由来増殖因子に対する安定化アプタマーおよび腫瘍治療剤としてのそれらの使用
JP4673217B2 (ja) * 2003-04-23 2011-04-20 由紀夫 佐藤 メチル化ＣｐＧポリヌクレオチド
US20050250106A1 (en) * 2003-04-24 2005-11-10 David Epstein Gene knock-down by intracellular expression of aptamers
RU2364419C2 (ru) * 2003-04-25 2009-08-20 Новартис Вэксинес Энд Дайэгностикс, Инк. Композиции, содержащие катионные микрочастицы и днк hcv е1е2, и способы их применения
EP1617845A4 (de) * 2003-04-28 2006-09-20 3M Innovative Properties Co Zusammensetzungen und verfahren zur induktion von opioid-rezeptoren
WO2004100965A1 (ja) * 2003-05-15 2004-11-25 Japan Science And Technology Agency 免疫刺激剤
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
WO2005020964A1 (en) 2003-06-02 2005-03-10 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
WO2005000884A1 (en) 2003-06-05 2005-01-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
EP2371834B1 (de) * 2003-06-11 2016-02-17 Idera Pharmaceuticals, Inc. Stabilisierte Oligonukleotide als Immunmodulatoren
JP2007524615A (ja) * 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
KR20060031607A (ko) * 2003-07-10 2006-04-12 사이토스 바이오테크놀로지 아게 패킹된 바이러스-양 입자
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
RU2006102188A (ru) * 2003-07-31 2006-07-10 ЗМ Инновейтив Пропертиз Компани (US) Биоактивные композиции, включающие триазины
WO2005016273A2 (en) * 2003-08-05 2005-02-24 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
JP2007502288A (ja) * 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ含有化合物
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
US8071652B2 (en) * 2003-08-21 2011-12-06 The Board Of Regents Of The University Of Texas System Method of treating irritable bowel syndrome
EP1660122A4 (de) * 2003-08-25 2007-10-24 3M Innovative Properties Co Immunstimulatorische kombinationen und behandlungen
AU2004268616B2 (en) * 2003-08-25 2010-10-07 3M Innovative Properties Company Delivery of immune response modifier compounds
EP1658076B1 (de) * 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy- und arylalkylenoxy-substituierte imidazochinoline
JP2007504172A (ja) * 2003-09-02 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 粘膜に関連した症状の処置に関する方法
AU2004270201A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
EP1670507A4 (de) 2003-09-12 2007-10-17 Antigenics Inc Vakzine zur behandlung und prävention von herpes simplex-virusinfektion
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
EP1670506B1 (de) 2003-10-02 2012-11-21 Novartis AG Flüssige vakzine für multiple meningokokken-serogruppen
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
BRPI0414856A (pt) * 2003-10-03 2006-11-21 3M Innovative Properties Co imidazoquinolinas alcóxi-substituìdas
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005034979A2 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
CA2540949A1 (en) * 2003-10-30 2005-05-12 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
WO2005041891A2 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
WO2005048945A2 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
US8691837B2 (en) * 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US20050287118A1 (en) * 2003-11-26 2005-12-29 Epitomics, Inc. Bacterial plasmid with immunological adjuvant function and uses thereof
US20050277127A1 (en) * 2003-11-26 2005-12-15 Epitomics, Inc. High-throughput method of DNA immunogen preparation and immunization
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
PL2336147T3 (pl) 2003-12-17 2015-01-30 Janssen Alzheimer Immunotherap Immunogenne koniugaty A beta z nośnikiem peptydowym i sposoby ich otrzymywania
AU2004299501B2 (en) 2003-12-17 2010-12-23 Wyeth Llc Immunogenic peptide carrier conjugates and methods of producing same
JP4817599B2 (ja) * 2003-12-25 2011-11-16 独立行政法人科学技術振興機構 免疫活性増強剤とこれを用いた免疫活性の増強方法
WO2005066170A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
EP1699398A4 (de) * 2003-12-30 2007-10-17 3M Innovative Properties Co Verbesserung der immunantworten
US8735421B2 (en) * 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
KR100558851B1 (ko) * 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
WO2005072290A2 (en) * 2004-01-23 2005-08-11 Joslin Diabetes Center Methods of treating, reducing, or preventing autoimmune conditions
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
EP1720568A2 (de) 2004-02-19 2006-11-15 Coley Pharmaceutical Group, Inc. Immunstimulatorische virale rna-oligonucleotide
CN1918293A (zh) * 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005090968A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
EP2545931A1 (de) 2004-03-19 2013-01-16 Herbs Spring, LLC Kräutertherapie zur Behandlung von Lebensmittelallergie
WO2005094531A2 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
EP1730281A2 (de) * 2004-04-02 2006-12-13 Coley Pharmaceutical Group, Inc. Immunstimulierende nukleinsäuren zur induzierung von il-10-antworten
US20050260755A1 (en) * 2004-04-06 2005-11-24 Isis Pharmaceuticals, Inc. Sequential delivery of oligomeric compounds
WO2005105106A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of macular degeneration
WO2005105107A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of multiple sclerosis
US7579450B2 (en) * 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
JP2008505857A (ja) * 2004-04-28 2008-02-28 スリーエム イノベイティブ プロパティズ カンパニー 粘膜ワクチン接種のための組成物および方法
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
BRPI0510315A (pt) 2004-04-30 2007-10-16 Chiron Srl integração de vacinação com conjugado meningocócico
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
CN1989439B (zh) * 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
CN1296378C (zh) * 2004-05-17 2007-01-24 中国人民解放军第三军医大学 高免疫活性 CpG－S ODN 和拮抗 CpG－S ODN 作用的 CpG－N ODN 的基因序列及其应用
EP1766094A4 (de) 2004-05-18 2009-11-25 Vical Inc Grippevirusimpfstoffzusammensetzung und verwendungsverfahren
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
WO2005116064A2 (en) 2004-05-21 2005-12-08 Wyeth Altered fibronectin-binding protein of staphylococcus aureus
HUE026644T2 (en) 2004-05-28 2016-07-28 Oryxe Mixture for transdermal administration of low and high molecular weight compounds
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
CA2569419A1 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
AU2005326144A1 (en) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
WO2005123080A2 (en) * 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
WO2006009826A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US20070259881A1 (en) * 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
EP1781325A2 (de) 2004-07-18 2007-05-09 CSL Limited Immunstimulierender komplex und oligonucleotidformulierungen zur induzierung verbesserter interferon-gamma-antworten
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
ATE548389T1 (de) 2004-08-03 2012-03-15 Innate Pharma Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor
EP1786450A4 (de) * 2004-08-27 2009-11-11 3M Innovative Properties Co Hiv-immunstimulatorische zusammensetzungen
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2006032697A2 (en) 2004-09-24 2006-03-30 Intercell Ag MODIFIED VPl-CAPSID PROTEIN OF PARVOVIRUS B19
JP2008000001A (ja) * 2004-09-30 2008-01-10 Osaka Univ 免疫刺激オリゴヌクレオチドおよびその医薬用途
EP2769735B1 (de) 2004-10-06 2017-04-19 MedImmune, LLC Kühlschranktemperaturstabile Grippeimpfstoff-zusammensetzungen
EP1797173B1 (de) 2004-10-08 2014-05-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Modulierung der replikationsrate durch verwendung von seltener verwendeten synonymen kodons
WO2006042254A2 (en) * 2004-10-08 2006-04-20 3M Innovative Properties Company Adjuvant for dna vaccines
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
CN101175508A (zh) 2004-10-21 2008-05-07 惠氏公司 表皮葡萄球菌多肽抗原的免疫原性组合物
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP3034089A1 (de) 2004-11-02 2016-06-22 Archemix LLC Stabilisierte aptamere für einen aus plättchen gewonnenen wachstumsfaktor und deren verwendung als onkologietherapeutika
US7332324B2 (en) 2004-12-03 2008-02-19 University Of Toledo Attenuated vaccine useful for immunizations against Coccidioides spp. infections
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
WO2006065751A2 (en) * 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
WO2006073760A2 (en) 2004-12-17 2006-07-13 Dana-Farber Cancer Institute, Inc. Regulation of mink in thymocytes and t lymphocytes
CA2592922A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
CA2594674C (en) 2004-12-30 2016-05-17 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
ES2538498T3 (es) 2004-12-30 2015-06-22 Meda Ab Utilización de Imiquimod para el tratamiento de metástasis cutáneas provenientes de un tumor de cáncer de mama
WO2006074003A2 (en) * 2004-12-30 2006-07-13 3M Innovative Properties Company CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
EP2433647A3 (de) 2005-01-27 2012-06-06 Children's Hospital & Research Center at Oakland Gna1870-basierte vesikelimpfstoffe für breitbandschutz gegen neisseria meningitidis-bedingte erkrankungen
CA2549423C (en) * 2005-01-28 2012-10-02 Hyung-Joo Kwon Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US9248127B2 (en) * 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CN101160401A (zh) * 2005-02-24 2008-04-09 科勒制药集团公司 免疫刺激寡核苷酸
NZ561144A (en) * 2005-03-04 2009-09-25 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
US8101345B1 (en) 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
EP1869043A2 (de) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridin-1,4-diamine und analoge davon
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2878579C (en) 2005-04-08 2018-01-23 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
EP1874325A2 (de) * 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Verfahren zur behandlung von durch infektionserkrankungen verschlimmertes asthma
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US20070003608A1 (en) * 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
CA2604683C (en) 2005-04-12 2019-04-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US8119146B2 (en) 2005-04-18 2012-02-21 Angelica Medina-Selby Expressing hepatitis B virus surface antigen for vaccine preparation
JP2008539252A (ja) * 2005-04-25 2008-11-13 スリーエム イノベイティブ プロパティズ カンパニー 免疫活性化組成物
US20060241076A1 (en) * 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US20090075342A1 (en) * 2005-04-26 2009-03-19 Sharon Cload Metabolic profile directed aptamer medicinal chemistry
WO2006133553A1 (en) 2005-06-14 2006-12-21 Protox Therapeutics Incorporated Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
MX2007016561A (es) 2005-06-30 2008-03-10 Archemix Corp Materiales y metodos para la generacion de transcriptos de acido nucleico completamente modificados en la posicion 2.
ATE476193T1 (de) 2005-07-01 2010-08-15 Index Pharmaceuticals Ab Immunstimulatorisches verfahren
DK2179737T3 (da) 2005-07-01 2013-11-11 Index Pharmaceuticals Ab Modulering af respons på steroider
NZ565311A (en) * 2005-07-07 2009-10-30 Pfizer Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
WO2007008904A2 (en) * 2005-07-08 2007-01-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
CA2615626A1 (en) 2005-07-18 2007-01-25 Novartis Ag Small animal model for hcv replication
WO2007012285A1 (fr) * 2005-07-28 2007-02-01 Changchun Huapu Biotechnology Co., Ltd. Desoxynucleosides monocatenaires resistant aux infections virales
WO2007088423A2 (en) * 2005-09-16 2007-08-09 Coley Pharmaceutical Gmbh Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
EA013375B1 (ru) * 2005-09-16 2010-04-30 Коли Фармасьютикал Гмбх МОДУЛЯЦИЯ ИММУНОСТИМУЛИРУЮЩИХ СВОЙСТВ КОРОТКОЙ ИНТЕРФЕРИРУЮЩЕЙ РИБОНУКЛЕИНОВОЙ КИСЛОТЫ (siРНК) С ПОМОЩЬЮ МОДИФИКАЦИИ НУКЛЕОТИДОВ
US20070081972A1 (en) * 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
EP1945247A1 (de) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mukosale und systemische immunisierungen mit alphavirus-replicon-teilchen
AU2006306805A1 (en) 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
CA2628328A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
HUE051122T2 (hu) 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
CN102864152B (zh) * 2005-11-07 2015-11-18 艾德拉药物股份有限公司 包含经修饰的免疫刺激性二核苷酸的基于寡核苷酸的化合物之免疫刺激特性
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
DK1957647T3 (en) 2005-11-25 2015-04-07 Zoetis Belgium S A Immunostimulatory oligoribonucleotides
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
PT2478916T (pt) 2006-01-27 2020-07-03 Seqirus Uk Ltd Vacinas de influenza que contêm hemaglutinina e proteínas da matriz
EP2405002B1 (de) * 2006-02-15 2014-09-24 AdiuTide Pharmaceuticals GmbH Zusammensetzungen und Verfahren für Oligonucleotidformulierungen
EP3085373A1 (de) 2006-02-22 2016-10-26 3M Innovative Properties Company Konjugate zur modifizierung von immunreaktionen
EP2253957B1 (de) 2006-03-14 2013-05-15 Oregon Health and Science University Verfahren zur Erzeugung einer Immunantwort auf Tuberculosis
CA2646891A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2382987A1 (de) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Lagerung von Influenza-Impfstoffen ohne Kühlung
CA2647942A1 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
WO2007119815A1 (ja) 2006-04-14 2007-10-25 Kyowa Hakko Kirin Co., Ltd. Ｔｏｌｌ様受容体９作動薬
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CA2653939C (en) 2006-05-31 2013-01-22 Toray Industries, Inc. Immunostimulatory oligonucleotides and use thereof in pharmaceuticals
US20080026986A1 (en) * 2006-06-05 2008-01-31 Rong-Fu Wang Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
CA2655108C (en) 2006-06-12 2019-05-07 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
CN101472610A (zh) 2006-06-20 2009-07-01 特朗斯吉有限公司 重组病毒疫苗
WO2008094183A2 (en) * 2006-07-11 2008-08-07 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US7906506B2 (en) * 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
ES2536401T3 (es) 2006-09-11 2015-05-25 Novartis Ag Fabricación de vacunas contra virus de la gripe sin usar huevos
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
DE102006050655A1 (de) * 2006-10-24 2008-04-30 Halmon Beheer B.V. Pharmazeutische Zusammensetzung zur Behandlung allergischer Erkrankungen
RU2009115687A (ru) * 2006-10-26 2010-11-10 Коли Фармасьютикал Гмбх (De) Олигорибонуклеотиды и их применения
EP2078197B1 (de) 2006-11-01 2016-03-23 Ventana Medical Systems, Inc. Haptene, haptenkonjugate, zusammensetzungen daraus und verfahren für ihre herstellung und verwendung
US20090142362A1 (en) * 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
CA2669137A1 (en) 2006-11-09 2008-06-19 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
ES2528166T3 (es) * 2006-11-15 2015-02-04 Eli Lilly And Company Métodos y composiciones para tratar la gripe
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2678404C (en) 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
JP2010523676A (ja) * 2007-04-13 2010-07-15 デューク ユニバーシティ ヒト免疫不全ウイルスに対する中和抗体を誘導する方法
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
EP2377952A1 (de) 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Verfahren zur Diagnostizierung und Behandlung von Astrozytoma
US20100285041A1 (en) 2007-05-17 2010-11-11 Eugen Uhlmann Class A Oligonucleotides with Immunostimulatory Potency
CA2687535C (en) * 2007-05-18 2017-08-22 Coley Pharmaceutical Gmbh Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity
EP3561513A1 (de) * 2007-05-23 2019-10-30 Ventana Medical Systems, Inc. Polymere träger für immunhistochemie und in-situ-hybridisierung
BRPI0811228A2 (pt) * 2007-05-24 2014-10-21 Glaxonsmithkline Biolog S A Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US7879812B2 (en) 2007-08-06 2011-02-01 University Of Iowa Research Foundation Immunomodulatory oligonucleotides and methods of use therefor
KR20100075843A (ko) * 2007-08-21 2010-07-05 다이나박스 테크놀로지 코퍼레이션 인플루엔자 단백질 조성물 및 그 제조 및 사용 방법
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
KR20100068422A (ko) * 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
US20110014231A1 (en) * 2007-11-05 2011-01-20 Mor Research Applications Ltd Anti-measles cancer immunotherapy
WO2009062112A2 (en) 2007-11-09 2009-05-14 The Salk Institute For Biological Studies Use of tam receptor inhibitors as antimicrobials
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP2011506334A (ja) 2007-12-07 2011-03-03 ノバルティス アーゲー 免疫応答を誘導するための組成物
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
CA2710350A1 (en) * 2007-12-21 2009-07-02 Wyeth Llc Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
CN101977610B (zh) * 2008-01-25 2012-05-16 奇默里克斯公司 治疗病毒感染的方法
RU2545701C2 (ru) * 2008-01-31 2015-04-10 Куревак Гмбх НУКЛЕИНОВЫЕ КИСЛОТЫ ФОРМУЛЫ (I) (NuGlXmGnNv)a И ИХ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИММУННОСТИМУЛИРУЮЩИХ АГЕНТОВ/АДЪЮВАНТОВ
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
EP2265640B1 (de) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimere faktor-h-bindende proteine (fhbp), die eine heterologe b-domäne enthalten, und anwendungsverfahren
EP2268309B1 (de) 2008-03-18 2015-01-21 Novartis AG Verbesserungen der herstellung von grippevirus-impstoff-antigenen
AU2009246169B2 (en) 2008-05-15 2015-01-22 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
WO2009143292A2 (en) 2008-05-21 2009-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating pneumoconiosis with oligodeoxynucleotides
ES2557594T3 (es) 2008-06-05 2016-01-27 Ventana Medical Systems, Inc. Método para el procesamiento histoquímico y el uso de una composición para el procesamiento histoquímico
EP2303318A2 (de) 2008-06-20 2011-04-06 Wyeth LLC Zusammensetzungen und verfahren zur verwendung von orf 1358 von beta-hämolytischen streptokokken-stämmen
JP5659332B2 (ja) 2008-06-27 2015-01-28 ゾエティス・エルエルシー 新規なアジュバント組成物
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
US20110136897A1 (en) * 2008-08-14 2011-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
WO2010027818A2 (en) 2008-08-25 2010-03-11 Dana-Farber Cancer Institute, Inc. Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
CA2737455A1 (en) 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations
EP2385371B1 (de) 2008-09-22 2014-10-22 Oregon Health and Science University Verfahren zum Erkennen einer Infektion mit dem Mycobakterium tuberculosis
DK2344522T3 (en) * 2008-10-16 2016-04-18 Univ Saskatchewan Combinatorial Adjuvant formulation
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
NZ592368A (en) 2008-11-05 2013-11-29 Wyeth Llc Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
US8329188B2 (en) * 2008-11-12 2012-12-11 Theraclone Sciences, Inc. Human M2e peptide immunogens
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
EP2376108B1 (de) * 2008-12-09 2017-02-22 Pfizer Vaccines LLC Ige ch3 peptidimpstoff
PT2376107E (pt) 2008-12-09 2014-07-25 Coley Pharm Group Inc Oligonucleotídeos imunoestimulantes
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
CN102307477B (zh) 2009-01-05 2015-07-29 埃皮托吉尼西斯股份有限公司 佐剂组合物及使用方法
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
MX2011007456A (es) 2009-01-12 2011-08-03 Novartis Ag Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
US8664183B2 (en) 2009-02-27 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SPANX-B polypeptides and their use
AU2010220103A1 (en) 2009-03-06 2011-09-22 Novartis Ag Chlamydia antigens
DK2411043T3 (da) 2009-03-23 2013-10-21 Pin Pharma Inc Behandling af cancer med immunostimulatorisk hiv tat derivat-polypeptider
US20120070458A1 (en) 2009-03-24 2012-03-22 Novartis Ag Adjuvanting meningococcal factor h binding protein
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2010114628A2 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
EP2413953B1 (de) 2009-04-03 2017-11-08 Agenus Inc. Methoden zur herstellung und verwendung von multichaperon-antigen-komplexen
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
KR20120022984A (ko) * 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Ｔｈ１ 편향 반응을 제공하는 면역나노치료법
ES2552153T3 (es) 2009-04-30 2015-11-26 Coley Pharmaceutical Group, Inc. Vacuna neumocócica y usos de la misma
AU2010254549B2 (en) 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
EP2442826B1 (de) 2009-06-15 2015-07-08 National University of Singapore Influenzaimpfstoff, zusammensetzung und seine verwendung
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
AR078601A1 (es) 2009-06-22 2011-11-23 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
ES2526996T3 (es) 2009-07-16 2015-01-19 Novartis Ag Inmunógenos desintoxicados de Escherichia coli
KR101346197B1 (ko) 2009-07-17 2014-02-06 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
PE20120817A1 (es) 2009-07-30 2012-07-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
AU2010284329B2 (en) * 2009-08-18 2015-04-16 Takeda Pharmaceutical Company Limited Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US8598327B2 (en) 2009-08-18 2013-12-03 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
KR101873179B1 (ko) 2009-08-26 2018-06-29 셀렉타 바이오사이언시즈, 인크. Ｔ－세포 도움을 유도하는 조성물
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
CA2846746A1 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
ES2594485T3 (es) 2009-10-07 2016-12-20 Uvic Industry Partnerships Inc. Vacunas que comprenden transgenes sensibles al calor
WO2011047340A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
JP5960055B2 (ja) 2009-10-27 2016-08-02 ノバルティス アーゲー 改変髄膜炎菌ｆＨＢＰポリペプチド
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2502076B1 (de) 2009-11-20 2018-04-18 Oregon Health and Science University Verfahren zum erkennen einer infektion mit dem mycobakterium tuberculosis
KR20120120185A (ko) 2009-12-22 2012-11-01 셀덱스 쎄라퓨틱스, 인크. 백신 조성물
PT2534150T (pt) 2010-02-12 2017-05-02 Chimerix Inc Métodos para tratar uma infecção viral
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
US8685416B2 (en) 2010-03-02 2014-04-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of cancer
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
WO2011112599A2 (en) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary. Department Of Health & Human Services Immunogenic pote peptides and methods of use
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EP2552942B1 (de) 2010-03-30 2017-12-27 Children's Hospital & Research Center at Oakland Faktor-h-bindende proteine (fhbp) mit geänderten eigenschaften und verwendungsverfahren dafür
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2556151A1 (de) 2010-04-07 2013-02-13 Novartis AG Verfahren zur erzeugung von virusähnlichen parvovirus-b19-partikeln
WO2011130379A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
WO2011139709A2 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
NO2569436T3 (de) 2010-05-14 2018-04-28
MX2012013713A (es) 2010-05-26 2013-01-28 Selecta Biosciences Inc Composiciones de nanovehiculos con adyuvante no acoplado.
US10456463B2 (en) 2010-05-28 2019-10-29 Zoetis Belgium S.A Vaccines comprising cholesterol and CpG as sole adjuvant-carrier molecules
CA2800913C (en) 2010-06-03 2019-07-23 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
DK2575870T3 (en) 2010-06-04 2017-02-13 Wyeth Llc vaccine Formulations
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
EP2585106A1 (de) 2010-06-25 2013-05-01 Novartis AG Kombinationen aus meningokokken-faktor-h-bindenden proteinen
EP3153578A1 (de) 2010-07-06 2017-04-12 Novartis Ag Immunogene zusammensetzungen aus norovirus und verfahren
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
ES2850973T3 (es) 2010-08-23 2021-09-01 Wyeth Llc Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
ES2585328T5 (es) 2010-09-10 2022-12-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
EP2616545B1 (de) 2010-09-14 2018-08-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Rechnerisch optimierte breit reaktive influenza-antigene
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2468866A1 (de) * 2010-12-21 2012-06-27 Index Pharmaceuticals AB Biologisch aktive Oligonukleotide zur Modulation des Immunsystems
HUE033072T2 (hu) 2010-12-22 2017-11-28 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
NZ612285A (en) 2010-12-22 2015-09-25 Bayer Ip Gmbh Enhanced immune response in bovine species
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
EP2471926A3 (de) * 2010-12-30 2012-07-11 Intervet International BV Immunstimulierende Oligodeoxynukleotide
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
JP6002691B2 (ja) 2011-02-11 2016-10-05 バクスアルタ ゲーエムベーハー 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
WO2012149307A2 (en) 2011-04-27 2012-11-01 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
LT2707385T (lt) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Iš anksto sulieti rsv f antigenai
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
WO2012160184A1 (en) * 2011-05-26 2012-11-29 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
CA2837227C (en) 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators
US9353115B2 (en) 2011-06-01 2016-05-31 Janus Biotherapeutics, Inc. Immune system modulators
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
CA2838023C (en) 2011-06-03 2019-08-13 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
WO2012174455A2 (en) 2011-06-17 2012-12-20 University Of Tennessee Research Foundation Group a streptococcus multivalent vaccine
US9580475B2 (en) 2011-06-20 2017-02-28 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
EP3508219A1 (de) 2011-07-06 2019-07-10 GlaxoSmithKline Biologicals S.A. Selbst-replizierende rna-prime - protein boost impfstoffe
EP3332802A1 (de) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
CN103764171B (zh) 2011-07-08 2016-08-17 诺华股份有限公司 酪氨酸连接方法
WO2013007703A1 (en) * 2011-07-08 2013-01-17 Universität Zürich CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS
DK2734208T3 (en) 2011-07-19 2017-06-19 Wave Life Sciences Ltd PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
ES2687129T3 (es) 2011-07-25 2018-10-23 Glaxosmithkline Biologicals Sa Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
EA201490381A1 (ru) 2011-07-29 2014-06-30 Селекта Байосайенсиз, Инк. Синтетические наноносители, которые стимулируют формирование гуморального иммунного ответа и иммунного ответа, опосредованного цитотоксическими т-лимфоцитами (ctl)
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
WO2013039792A1 (en) 2011-09-12 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogens based on an hiv-1 gp120 v1v2 epitope
US9511130B2 (en) 2011-09-14 2016-12-06 Glaxosmithkline Biologicals Sa Escherichia coli vaccine combination
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
AU2012318694B2 (en) 2011-10-04 2016-12-22 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
EP2768847A4 (de) 2011-10-20 2015-11-11 Us Gov Health & Human Serv E-glycoprotein-polypeptide des dengue-virus mit mutationen zur eliminierung von immundominanten kreuzreaktiven epitopen
US9493517B2 (en) 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule
US9694063B2 (en) 2011-12-08 2017-07-04 Glaxosmithkline Biologicals Sa Clostridium difficile toxin-based vaccine
EA201491081A1 (ru) 2012-01-16 2016-11-30 Элизабет Маккенна Композиции и способы для лечения заболеваний и расстройств печени
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
AU2013217166B2 (en) 2012-02-07 2017-04-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
WO2013122827A1 (en) 2012-02-13 2013-08-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
US20150273042A1 (en) 2012-02-24 2015-10-01 Novartis Ag Pilus proteins and compositions
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX2018011291A (es) 2012-03-09 2023-01-31 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
CA2866185C (en) 2012-03-23 2021-04-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pathogenic phlebovirus isolates and compositions and methods of use
EP2841098A4 (de) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanopartikel zur behandlung von allergien
ES2837825T3 (es) 2012-04-26 2021-07-01 Glaxosmithkline Biologicals Sa Antígenos y combinaciones de antígenos
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
US10076535B2 (en) 2012-04-27 2018-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing
PE20142406A1 (es) 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
CN104736180A (zh) 2012-05-22 2015-06-24 诺华股份有限公司 脑膜炎球菌血清组x偶联物
WO2013177291A1 (en) 2012-05-23 2013-11-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof
US9427476B2 (en) 2012-05-24 2016-08-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent meningococcal conjugates and methods for preparing conjugates
US9687542B2 (en) 2012-06-19 2017-06-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Rift valley fever virus replicon particles and use thereof
JP6157607B2 (ja) 2012-06-19 2017-07-05 ボルボ ラストバグナー アーベー ガス流を制御するための装置、排気後処理システム、及び車両を推進するシステム
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN104853770A (zh) 2012-07-06 2015-08-19 诺华股份有限公司 免疫原性组合物及其应用
CN104684923B (zh) * 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
KR101850319B1 (ko) 2012-07-13 2018-04-20 웨이브 라이프 사이언시스 리미티드 비대칭 보조 그룹
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
CA2879443A1 (en) 2012-07-19 2014-01-23 Zoetis Llc Bovine influenza virus compositions
EP2877598A1 (de) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutationen im zusammenhang mit der resistenz gegenüber hemmern der bruton-tyrosinkinase (btk)
AU2013295770A1 (en) 2012-07-27 2015-01-29 Zoetis Services Llc Tick toxin compositions
DK2885007T3 (en) 2012-08-16 2018-12-03 Pfizer Methods for glycoconjugation and compositions
EP3639851A1 (de) 2012-09-04 2020-04-22 Bavarian Nordic A/S Verfahren und zusammensetzungen zur verbesserung von impfstoffimmunreaktionen
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
WO2014047588A1 (en) 2012-09-21 2014-03-27 Elizabeth Mckenna Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
US9562066B2 (en) * 2012-09-25 2017-02-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
AU2013326503B2 (en) 2012-10-03 2018-04-19 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20150080592A (ko) 2012-11-02 2015-07-09 파마시클릭스, 인코포레이티드 Tec 패밀리 키나제 억제제 애쥬번트 요법
WO2014074785A1 (en) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
TWI465241B (zh) 2012-12-19 2014-12-21 Ind Tech Res Inst 圓柏（Ｊｕｎｉｐｅｒｕｓ ｃｈｉｎｅｎｓｉｓ）萃取物或木酚素（ｌｉｇｎａｎ）用於製造抑制血管新生之藥物的用途
CN106177933B (zh) 2012-12-20 2020-09-29 辉瑞公司 免疫原性组合物
EP2948469A4 (de) 2013-01-23 2016-11-02 Univ Leland Stanford Junior Stabilisiertes hepatitis-b-kern-polypeptid
EP2953638B1 (de) 2013-02-07 2023-07-05 Children's Medical Center Corporation Proteinantigene zum schutz gegen pneumokokkenkolonisation und/oder -befall
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
CA2902560A1 (en) 2013-03-14 2014-09-25 President And Fellows Of Harvard College Nanoparticle-based compositions
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
CA2907098A1 (en) 2013-03-15 2014-09-25 Zoetis Services Llc Cross-protection of bovines against b. trehalosi infection by a multi-valent vaccine
EP3760223A1 (de) 2013-04-03 2021-01-06 N-Fold Llc Neuartige nanopartikelzusammensetzungen
CA2909721A1 (en) 2013-04-19 2014-10-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lone star virus
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
CN103550783A (zh) * 2013-04-27 2014-02-05 中国人民解放军军事医学科学院放射与辐射医学研究所 一种核酸类药物靶向递送系统及其制备方法
WO2015132619A1 (en) 2013-05-15 2015-09-11 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
CN105530957B (zh) * 2013-07-19 2022-03-29 台湾卫生研究院 CpG寡脱氧核苷酸、包含其的免疫组合物及组合物用于制备治疗以刺激免疫反应的药物的应用
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
EP3632458A1 (de) 2013-07-26 2020-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Verbindungen und pharmazeutische zusammensetzungen zur behandlung von bakterieninfektionen
KR101905278B1 (ko) 2013-09-08 2018-10-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
KR102257743B1 (ko) 2013-09-19 2021-05-28 조에티스 서비시즈 엘엘씨 유성 아쥬반트
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
EP3052517B1 (de) 2013-09-30 2023-07-19 Triad National Security, LLC Hiv-immunogen-polypeptid mit konservierten mosaikregionen
US9663556B2 (en) 2013-10-04 2017-05-30 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
ES2715890T3 (es) 2013-11-01 2019-06-06 Pfizer Vectores de expresión de antígenos asociados a la próstata
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
NZ719934A (en) 2013-11-28 2022-10-28 Bavarian Nordic As Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
US10182988B2 (en) * 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
EP3079716B1 (de) 2013-12-13 2019-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multi-epitop tarp-peptid-impfstoff und seine verwendungen
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP3095460A4 (de) * 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
JPWO2015108047A1 (ja) * 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108048A1 (ja) * 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
SG10201912897UA (en) 2014-01-16 2020-02-27 Wave Life Sciences Ltd Chiral design
RU2743793C1 (ru) 2014-01-21 2021-02-26 Пфайзер Инк. Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2015208820B2 (en) 2014-01-21 2020-05-14 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
AU2015208821B2 (en) 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2015209575A1 (en) 2014-01-21 2016-07-21 Immune Design Corp. Compositions for use in the treatment of allergic conditions
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
EP3104877B1 (de) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9-impfstoff und verfahren zur verwendung davon
EP3443983B1 (de) 2014-02-14 2022-07-20 Pfizer Inc. Immunogene glykoproteinkonjugate
GB2523187A (en) 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
EP3110401A4 (de) 2014-02-25 2017-10-25 Merck Sharp & Dohme Corp. Lipidnanopartikel-impfstoffadjuvanzien und antigenfreisetzungssysteme
WO2015128461A1 (en) * 2014-02-28 2015-09-03 Bayer Animal Health Gmbh Immunostimulatory plasmids
US10034934B2 (en) 2014-03-11 2018-07-31 Regents Of The University Of Minnesota Porcine epidemic diarrhea virus vaccines and methods of use thereof
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
KR102297357B1 (ko) 2014-03-26 2021-09-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 돌연변이 스태필로코쿠스 항원
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
US10111948B2 (en) 2014-04-25 2018-10-30 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
AU2015263888A1 (en) * 2014-05-23 2017-01-19 Gregory CAUCHON Coating method and materials
EP3149479A2 (de) 2014-05-30 2017-04-05 Sanofi Pasteur Inc. Expression und konformationelle analyse von manipuliertem influenza-hämagglutinin
CA2953216C (en) 2014-06-04 2020-12-22 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US20150374815A1 (en) 2014-06-25 2015-12-31 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
WO2016011083A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
EP3398948A3 (de) 2014-08-22 2018-12-05 Janus Biotherapeutics, Inc. 2,4,6,7-tetrasubstituierte pteridinverbindungen und verfahren zur synthese und verwendung davon
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
SG11201702656WA (en) 2014-10-06 2017-04-27 Exicure Inc Anti-tnf compounds
US20160129097A1 (en) * 2014-11-06 2016-05-12 Jeremy Delk Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2016103531A1 (ja) * 2014-12-26 2016-06-30 国立研究開発法人医薬基盤・健康・栄養研究所 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用
WO2016109310A1 (en) 2014-12-31 2016-07-07 Checkmate Pharmaceuticals, Llc Combination tumor immunotherapy
DK3244917T3 (da) 2015-01-15 2023-05-22 Pfizer Immunogene sammensætninger til anvendelse i pneumokokvacciner
PL3244920T3 (pl) 2015-01-16 2023-09-25 Zoetis Services Llc Szczepionka przeciw pryszczycy
WO2016131048A1 (en) 2015-02-13 2016-08-18 Icahn School Of Medicine At Mount Sinai Rna containing compositions and methods of their use
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2016228514B2 (en) 2015-03-12 2021-06-17 Zoetis Services Llc Pyolysin methods and compositions
PE20180172A1 (es) 2015-05-04 2018-01-22 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
WO2016183371A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for the treatment or prevention of ischemic tissue damage
US10584148B2 (en) 2015-06-02 2020-03-10 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
WO2016200787A2 (en) 2015-06-09 2016-12-15 The Board Of Regents Of The University Of Oklahoma Compositions and treatments for haemophilus influenzae
US10954492B2 (en) 2015-06-10 2021-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Processes for production and purification of nucleic acid-containing compositions
AU2016281904B2 (en) 2015-06-26 2022-08-11 Seqirus UK Limited Antigenically matched influenza vaccines
US10449212B2 (en) 2015-07-09 2019-10-22 National Institute For Materials Science Immunostimulating oligonucleotide complex
NZ739007A (en) 2015-07-21 2022-08-26 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3328424A1 (de) 2015-07-31 2018-06-06 Bayer Animal Health GmbH Erhöhte immunreaktion in schweinen
BR112018002919B1 (pt) 2015-08-14 2024-02-27 Zoetis Services Llc Composição imunogênica eficaz compreendendo uma cepa de mycoplasma bovis e usos da mesma para prevenção de doenças causadas por mycoplasma bovis
US10709758B2 (en) 2015-09-03 2020-07-14 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile toxin B (TcdB) toxin
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
EP3349717A4 (de) 2015-09-17 2019-04-17 JRX Biotechnology, Inc. Ansätze zur verbesserung der hauthydrierung oder -befeuchtung
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
AU2016343845B2 (en) 2015-10-30 2023-04-13 Baylor College Of Medicine Compositions and methods for the treatment of HER2-expressing solid tumors
EP3377098A1 (de) 2015-11-20 2018-09-26 Pfizer Inc Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
US10596248B2 (en) 2015-12-09 2020-03-24 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
WO2017123201A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
PL3407910T3 (pl) 2016-01-29 2022-08-16 Bavarian Nordic A/S Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
WO2017189448A1 (en) 2016-04-25 2017-11-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bivalent immunogenic conjugate for malaria and typhoid
US20190298824A1 (en) 2016-05-04 2019-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Albumin-binding immunomodulatory compositions and methods of use thereof
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
EP3464328A1 (de) 2016-06-02 2019-04-10 Sanofi Pasteur Inc. Manipulierte influenza-antigen-polypeptide und immunogene zusammensetzungen davon
US11116832B2 (en) 2016-06-03 2021-09-14 Sanofi Pasteur Inc. Modification of engineered influenza hemagglutinin polypeptides
EP3468590A1 (de) 2016-06-13 2019-04-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Nukleinsäuren zur codierung von zika-virus-ähnlichen partikeln und deren verwendung in zika-virus-impfstoffen und diagnostischen tests
EP3474890A1 (de) 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. Pneumokokken-polysaccharid-proteinkonjugat-zusammensetzung
EP3269385A1 (de) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
EP3481849A1 (de) 2016-07-08 2019-05-15 The U.S.A. as represented by the Secretary, Department of Health and Human Services Attenuierte zikavirus-lebendimpfstoffe mit chimären dengue-/zika-viren
US10632185B2 (en) 2016-07-08 2020-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/zika viruses and methods of use
MX2019001341A (es) 2016-08-05 2019-07-04 Sanofi Pasteur Inc Composicion de conjugado de polisacarido neumococico multivalente-proteina.
JP7001687B2 (ja) 2016-08-05 2022-02-04 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物
US10182146B2 (en) * 2016-08-22 2019-01-15 Nice Ltd. System and method for dynamic redundant call recording
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US10172933B2 (en) 2016-10-31 2019-01-08 The United States Of America, As Represented By The Secretary Of Agriculture Mosaic vaccines for serotype a foot-and-mouth disease virus
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
ES2911490T3 (es) 2017-01-20 2022-05-19 Pfizer Composiciones inmunogénicas para su uso en vacunas antineumocócicas
KR102567845B1 (ko) 2017-01-31 2023-08-17 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
WO2018141029A1 (en) 2017-02-06 2018-08-09 Meat & Livestock Australia Limited Immunostimulating compositions and uses therefore
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
US10525119B2 (en) 2017-03-31 2020-01-07 Boston Medical Center Corporation Methods and compositions using highly conserved pneumococcal surface proteins
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
CA3066915A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
BR112019027387A8 (pt) 2017-06-23 2022-12-06 Univ Maryland Composições imunogênicas
US11464845B2 (en) 2017-07-21 2022-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neisseria meningitidis immunogenic compositions
CA3074708A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019048631A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited SMALL HNF4A ACTIVATOR RNA COMPOSITIONS AND METHODS OF USE
US11806364B2 (en) 2017-09-28 2023-11-07 Industry-Academic Cooperation Foundation, Yonsei University Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and methods thereof
EP3703745B1 (de) 2017-11-04 2024-04-10 Nevada Research & Innovation Corporation Immunogene konjugate und verfahren zur verwendung davon
PE20201338A1 (es) 2017-12-06 2020-11-25 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos
WO2019126197A1 (en) 2017-12-18 2019-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacterial polysaccharide-conjugated carrier proteins and use thereof
CA3086205A1 (en) 2017-12-19 2019-06-27 Massachusetts Institute Of Technology Antigen-adjuvant coupling reagents and methods of use
EP3743107A1 (de) 2018-01-22 2020-12-02 The United States of America, as represented by the Secretary, Department of Health and Human Services Inaktivierter influenzavirus-impfstoff mit breitem schutzspektrum
KR20200128116A (ko) 2018-02-28 2020-11-11 화이자 인코포레이티드 Il-15 변이체 및 이의 용도
MX2020009149A (es) * 2018-03-02 2021-01-15 Elicio Therapeutics Inc Compuestos que incluyen una secuencia de kras mutante y un lipido y usos de los mismos.
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
EP3774884B1 (de) 2018-03-28 2023-12-06 Sanofi Pasteur Inc. Verfahren zur erzeugung von breit schützenden impfstoffzusammensetzungen mit hämagglutinin
WO2019195314A2 (en) 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
BR112020019938A2 (pt) 2018-04-03 2021-01-26 Sanofi polipeptídeos antigênicos de vírus sincicial respiratório
JP2021519600A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性インフルエンザ−フェリチンポリペプチド
JP2021519599A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性ｏｓｐａポリペプチド
EP3773698A1 (de) 2018-04-03 2021-02-17 Sanofi Ferritinproteine
EP3797121A1 (de) 2018-05-23 2021-03-31 Pfizer Inc Cd3-spezifische antikörper und verwendungen davon
CA3100829A1 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
EP3574915A1 (de) 2018-05-29 2019-12-04 Neovacs Immunogenes produkt mit il-4 und/oder il-13 zur behandlung von erkrankungen im zusammenhang mit aberranter il-4- und/oder il-13-expression oder -aktivität
CN110004150B (zh) * 2018-08-01 2023-03-10 中国农业科学院兰州兽医研究所 一种具有免疫增强活性的CpG寡聚核苷酸序列及其应用
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220031830A1 (en) 2018-12-04 2022-02-03 The Rockefeller University Hiv vaccine immunogens
EP3893926A1 (de) 2018-12-12 2021-10-20 Pfizer Inc. Immunogene multiple hetero-antigen-polysaccharid-protein-konjugate und deren verwendung
US20220023413A1 (en) 2018-12-12 2022-01-27 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
WO2020123989A1 (en) 2018-12-14 2020-06-18 University Of Georgia Research Foundation, Inc. Crimean-congo hemorrhagic fever virus replicon particles and use thereof
AU2019401535B2 (en) 2018-12-19 2023-12-14 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
CN114269373A (zh) 2019-04-02 2022-04-01 赛诺菲 抗原性多聚呼吸道合胞病毒多肽
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3966331A4 (de) * 2019-05-10 2023-07-05 Microbio (Shanghai) Co., Ltd. Dimere cpg-oligonukleotide zur verwendung bei der modulation von immunantworten
US20210008110A1 (en) * 2019-06-14 2021-01-14 Serhat Gumrukcu Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
US20220280636A1 (en) 2019-07-19 2022-09-08 Merck Sharp & Dohme Corp. Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof
MX2022001190A (es) 2019-07-30 2022-02-22 Phibro Animal Health Corporation Una composicion para administracion en la mucosa para aves.
CN114728050A (zh) 2019-07-31 2022-07-08 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法
JP2022545181A (ja) 2019-08-30 2022-10-26 ユニバーシティ オブ ロチェスター がん治療のためのセプチン阻害剤
CN110646557A (zh) * 2019-10-12 2020-01-03 北京航空航天大学 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2022006578A (es) 2019-12-17 2022-07-04 Pfizer Anticuerpos especificos para cd47, pd-l1 y sus usos.
US20230039456A1 (en) 2019-12-17 2023-02-09 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Live attenuated leishmania parasite vaccines with enhanced safety characteristics
US20230241196A1 (en) 2020-01-27 2023-08-03 Oregon State University Gonorrhea subunit vaccine
BR112022015994A2 (pt) 2020-02-13 2022-10-11 Univ Illinois Composição imunogênica multivalente, vetor recombinante, célula hospedeira recombinante, e, métodos para induzir uma resposta imune protetora e para imunizar um animal contra dirofilariose
PE20230170A1 (es) 2020-02-23 2023-02-01 Pfizer Composiciones de escherichia coli y sus metodos
JP2023515829A (ja) 2020-02-28 2023-04-14 サノフィ パスツール インコーポレイテッド 小児対象のための高用量インフルエンザワクチン
US11213482B1 (en) 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
US20230146256A1 (en) 2020-04-17 2023-05-11 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
EP3900739A1 (de) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
EP4149440A1 (de) 2020-05-11 2023-03-22 Erytech Pharma Erythrozyten-extrazellularvesikel (rbevs) mit frachten sowie verfahren zur verwendung und herstellung davon
JP2023533793A (ja) 2020-07-17 2023-08-04 ファイザー・インク 治療用抗体およびそれらの使用
AU2021332183A1 (en) 2020-08-26 2023-03-02 Pfizer Inc. Group B streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
EP4213874A1 (de) 2020-09-17 2023-07-26 Neovacs Immunogenes produkt mit einem ige-fragment zur behandlung von ige-vermittelten entzündungserkrankungen
JP2023542528A (ja) 2020-09-24 2023-10-10 フレッド ハッチンソン キャンサー センター Ｓｏｘ２抗原を標的とする免疫療法
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
PE20231934A1 (es) 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
JP2022075575A (ja) 2020-11-04 2022-05-18 ファイザー・インク 肺炎球菌ワクチンにおける使用のための免疫原性組成物
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
EP4288087A1 (de) 2021-02-03 2023-12-13 The Board of Trustees of the University of Illinois Impfstoff und verfahren zur vorbeugung von filariasis und dirofilariasis
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112023023671A2 (pt) 2021-05-28 2024-02-06 Pfizer Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
WO2022261251A1 (en) 2021-06-08 2022-12-15 Glyde Bio Inc. Immunogenic compositions comprising tumour-associated antigen
EP4104830A1 (de) 2021-06-16 2022-12-21 Burghardt Wittig Sequentielle angeborene und adaptive immunmodulation zur krebsbehandlung
WO2023288263A1 (en) 2021-07-16 2023-01-19 The Board Of Trustees Of The University Of Illinois Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
WO2023018817A1 (en) 2021-08-11 2023-02-16 Sanofi Pasteur Inc. Truncated influenza neuraminidase and methods of using the same
WO2023059857A1 (en) 2021-10-08 2023-04-13 Sanofi Pasteur Inc. Multivalent influenza vaccines
WO2023079113A1 (en) 2021-11-05 2023-05-11 Sanofi Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
AR127585A1 (es) 2021-11-05 2024-02-07 Sanofi Sa Vacuna de arn de virus sincicial respiratorio
WO2023081798A1 (en) 2021-11-05 2023-05-11 Sanofi Pasteur Inc. Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
WO2023102388A1 (en) 2021-11-30 2023-06-08 Sanofi Pasteur Inc. Human metapneumovirus viral vector-based vaccines
US20230310571A1 (en) 2021-11-30 2023-10-05 Sanofi Pasteur Inc. Human metapneumovirus vaccines
WO2023111262A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023144206A1 (en) 2022-01-27 2023-08-03 Sanofi Pasteur Modified vero cells and methods of using the same for virus production
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023177579A1 (en) 2022-03-14 2023-09-21 Sanofi Pasteur Inc. Machine-learning techniques in protein design for vaccine generation
WO2023201109A1 (en) 2022-04-15 2023-10-19 Yale University Exatecan formulation
WO2023214082A2 (en) 2022-05-06 2023-11-09 Sanofi Signal sequences for nucleic acid vaccines
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer

Family Cites Families (524)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US2005A (en) * 1841-03-16 Improvement in the manner of constructing molds for casting butt-hinges
US2010A (en) * 1841-03-18 Machine foe
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US3521637A (en) * 1967-11-28 1970-07-28 Nelson J Waterbury Tampon or similar sanitary napkin containing vitamin a
US3627874A (en) 1969-07-16 1971-12-14 Merck & Co Inc Vaccine preparation
US3761585A (en) 1971-04-05 1973-09-25 Beecham Group Ltd Vaccines containing modified allergenic material
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
DE2643213C2 (de) 1976-09-25 1985-02-21 Bayer Ag, 5090 Leverkusen Verfahren zum Abschwächen oder Inaktivieren von Mikroorganismen
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
JP2547714B2 (ja) 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド オリゴヌクレオチド治療剤及びその製法
ES507187A0 (es) 1981-11-16 1983-01-01 Union Ind Y Agro Ganader S A U Procedimiento de obtencion de una leche humanizada adiciona-da de nucleotidos con destino a la alimentacion infantil.
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5308626A (en) * 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
EP0231039B1 (de) 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Verfahren zur Herstellung immunologischer Komplexe und diese enthaltende pharmazeutische Zusammensetzung
US4806463A (en) 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5059519A (en) 1986-07-01 1991-10-22 University Of Massachusetts Medical School Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
ES2007350A6 (es) 1987-05-29 1989-06-16 Ganadera Union Ind Agro Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
CA1339596C (en) 1987-08-07 1997-12-23 New England Medical Center Hospitals, Inc. Viral expression inhibitors
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5112605A (en) * 1989-03-17 1992-05-12 Genentech, Inc. Temporal gamma-interferon administration for allergies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5629158A (en) * 1989-03-22 1997-05-13 Cemu Bitecknik Ab Solid phase diagnosis of medical conditions
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US5178860A (en) 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
US5399676A (en) * 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5786189A (en) 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
US5457189A (en) 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5514577A (en) * 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5248670A (en) 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
WO1991019813A1 (en) 1990-06-11 1991-12-26 The University Of Colorado Foundation, Inc. Nucleic acid ligands
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5245022A (en) * 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5591720A (en) 1990-08-16 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating the effects of cytomegalovirus infections
US6042838A (en) 1991-02-15 2000-03-28 Uab Research Foundation immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA)
WO1992016192A1 (en) * 1991-03-15 1992-10-01 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
US5683985A (en) 1991-04-18 1997-11-04 The Salk Institute For Biological Studies Oligonucleotide decoys and methods relating thereto
US5498410A (en) * 1991-04-22 1996-03-12 Gleich; Gerald J. Method for the treatment of eosinophil-associated conditions with anionic polymers
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
WO1994008003A1 (en) 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
EP0587749A4 (en) 1991-05-31 1995-08-30 Genta Inc Compositions and delivery systems for transdermal administration of neutral oligomers
US5582986A (en) 1991-06-14 1996-12-10 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
US6030954A (en) * 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5576302A (en) 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
WO1993009789A1 (en) 1991-11-15 1993-05-27 Temple University - Of The Commonwealth System Of Higher Education Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene
JPH07501694A (ja) 1991-11-18 1995-02-23 タノックス　バイオシステムズ　インコーポレイテッド 免疫グロブリン生産のアイソタイプ特異的抑制のためのアンチセンスオリゴヌクレオチド
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
JPH07503615A (ja) 1992-02-04 1995-04-20 カイロン　コーポレイション 肝炎療剤
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US6498147B2 (en) 1992-05-22 2002-12-24 The Scripps Research Institute Suppression of nuclear factor-κb dependent processes using oligonucleotides
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5726518A (en) * 1992-07-22 1998-03-10 Nikon Corporation Supporting device of relative moving element of vibration actuator or vibration motor
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
AU678769B2 (en) 1992-07-27 1997-06-12 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
US6107062A (en) * 1992-07-30 2000-08-22 Inpax, Inc. Antisense viruses and antisense-ribozyme viruses
WO1994004196A1 (en) 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy
US5429199A (en) * 1992-08-26 1995-07-04 Kennametal Inc. Cutting bit and cutting insert
AU678415B2 (en) 1992-10-05 1997-05-29 Hybridon, Inc. Therapeutic anti-HIV oligonucleotide and pharmaceutical
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
EP0692972B2 (de) * 1993-04-02 2012-03-21 AntiCancer, Inc. Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
US5567604A (en) 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
SG54115A1 (en) * 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
US5840497A (en) 1993-06-11 1998-11-24 The Commonwealth Of Australia Commonwealth Scientific And Industrial Research Organization Method for specific silencing of genes by DNA methylation
KR960703170A (ko) * 1993-06-23 1996-06-19 알버트 디. 프리센. 안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection)
WO1995003407A2 (en) 1993-07-19 1995-02-02 Gen-Probe Incorporated Oligonucleotides with activity against human immunodeficiency virus
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US6605708B1 (en) 1993-07-28 2003-08-12 Hybridon, Inc. Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom
AU705889B2 (en) 1993-08-26 1999-06-03 Regents Of The University Of California, The Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US20030109469A1 (en) 1993-08-26 2003-06-12 Carson Dennis A. Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE69432315T2 (de) 1993-12-23 2004-02-12 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT
US5712384A (en) 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5646126A (en) 1994-02-28 1997-07-08 Epoch Pharmaceuticals Sterol modified oligonucleotide duplexes having anticancer activity
EP0804249A2 (de) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeres system zur freisetzung von genen
US5596091A (en) * 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5696248A (en) 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2267100T5 (es) 1994-07-15 2011-04-08 The University Of Iowa Research Foundation Oligonucleótidos inmunomoduladores.
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
JPH10502820A (ja) 1994-07-18 1998-03-17 ユニバーシティ・オブ・ノース・カロライナ・アット・チャペル・ヒル 腫瘍増殖、浸潤および転移を阻害するためのオリゴヌクレオシド化合物および方法
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US5785992A (en) * 1994-09-30 1998-07-28 Inex Pharmaceuticals Corp. Compositions for the introduction of polyanionic materials into cells
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
AU3559695A (en) * 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
WO1996012008A1 (en) 1994-10-13 1996-04-25 Merck & Co., Inc. Synthesis of methylase-resistant genes
US6630455B1 (en) 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
PL321711A1 (en) 1995-02-09 1997-12-22 Icn Pharmaceuticals Methods of and compositions for controlling the cd28 expression
US5932556A (en) 1995-09-17 1999-08-03 Tam; Robert C Methods and compositions for regulation of CD28 expression
GB9505438D0 (en) 1995-03-17 1995-05-03 Sod Conseils Rech Applic Antisense oligonucleotides
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
AU716486B2 (en) 1995-04-13 2000-02-24 Milkhaus Laboratory, Inc. Methods for treating respiratory disease
US6096721A (en) * 1995-04-13 2000-08-01 Milkhaus Laboratory, Inc. Method for treating mucositis by sublingual administration of DNA
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5858987A (en) * 1995-05-05 1999-01-12 Mitotix, Inc. E6AP antisense constructs and methods of use
RU2205874C2 (ru) 1995-05-11 2003-06-10 Апплайд Резеч Системз Арс Холдинг Н.В. Нуклеотидная последовательность, способная ингибировать активность il-6, плазмидный вектор для трансфекции в клетки млекопитающих, нуклеотидная последовательность, используемая при терапии, фармацевтическая композиция (варианты)
US5955059A (en) * 1995-06-06 1999-09-21 Trustees Of Boston University Use of locally applied DNA fragments
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5994315A (en) 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7034007B1 (en) * 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
AU723163B2 (en) 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5830878A (en) 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
JPH11510142A (ja) 1995-07-21 1999-09-07 ブラウン・ユニバーシティ・リサーチ・ファンデーション 核酸負荷ポリマー微粒子を使用した遺伝子治療法
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US5968909A (en) 1995-08-04 1999-10-19 Hybridon, Inc. Method of modulating gene expression with reduced immunostimulatory response
US6667293B1 (en) * 1995-09-12 2003-12-23 Hybridon, Inc. Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response
WO1997012633A1 (en) 1995-10-04 1997-04-10 Immunex Corporation Dendritic cell stimulatory factor
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
JP4359654B2 (ja) 1996-01-30 2009-11-04 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
SE9600648D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US5843770A (en) 1996-03-11 1998-12-01 The Immune Response Corporation Antisense constructs directed against viral post-transcriptional regulatory sequences
US6620805B1 (en) 1996-03-14 2003-09-16 Yale University Delivery of nucleic acids by porphyrins
US6030955A (en) * 1996-03-21 2000-02-29 The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof
US6121247A (en) 1996-03-29 2000-09-19 The Johns Hopkins University Therapy for allergic diseases
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
AU705647B2 (en) 1996-07-10 1999-05-27 Immunex Corporation Method of activating dendritic cells
EP1342477A1 (de) 1996-07-16 2003-09-10 Archibald James Mixson, M.D. Kationisches Vehikel: DNS Komplexe und ihre Verwendung in Gentherapie
US5854418A (en) 1996-07-25 1998-12-29 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpesvirus (KSHV) viral macrophage inflammatory protein-1α II (vMIP-1α II) and uses thereof
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
DE19637223A1 (de) * 1996-09-13 1998-04-09 Beiersdorf Ag Wiederlösbare, selbstklebende Vorrichtung
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6562345B1 (en) * 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
SE9604296D0 (sv) 1996-11-22 1996-11-22 Astra Ab New pharmaceutical formulation of polypeptides
FR2757876B1 (fr) 1996-12-27 1999-04-09 Biovector Therapeutics Sa Conjuges d'un vecteur particulaire et d'oligonucleotides, leur procede de preparation et les compositions pharmaceutiques les contenant
IL130192A0 (en) 1996-12-27 2000-06-01 Icn Pharmaceuticals G-rich oligo aptamers and method of modulating an immune response
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US20030064945A1 (en) * 1997-01-31 2003-04-03 Saghir Akhtar Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
GB9702021D0 (en) 1997-01-31 1997-03-19 Imperial College Medicaments
US7517952B1 (en) * 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU738513B2 (en) * 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1005368B1 (de) * 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
US20030104044A1 (en) * 1997-05-14 2003-06-05 Semple Sean C. Compositions for stimulating cytokine secretion and inducing an immune response
US6287591B1 (en) 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
EP0983289A4 (de) 1997-05-19 2001-04-25 Merck & Co Inc Oligonukleotidhilfsmittel
EP1003531B1 (de) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Verfahren zur Herstellung von Nukleinsäurekonstrukten
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
ATE432348T1 (de) * 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6221882B1 (en) * 1997-07-03 2001-04-24 University Of Iowa Research Foundation Methods for inhibiting immunostimulatory DNA associated responses
AU8428998A (en) 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
EP1007657B1 (de) 1997-08-19 2006-02-08 Idera Pharmaceuticals, Inc. Hiv-spezifische oligonukleotide und verfahren zu deren verwendung
JP4663113B2 (ja) * 1997-09-05 2011-03-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
US6749856B1 (en) 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
CA2312900A1 (en) * 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
AU1656799A (en) 1997-12-12 1999-07-05 Inex Pharmaceuticals Corp. Cationic drugs encapsulated in anionic liposomes
US7393630B2 (en) * 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
WO1999033493A1 (en) 1997-12-23 1999-07-08 Inex Pharmaceuticals Corporation Polyamide oligomers
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
JPH11209289A (ja) * 1998-01-22 1999-08-03 Taisho Pharmaceut Co Ltd 粘膜免疫誘起剤
ES2289200T3 (es) 1998-02-25 2008-02-01 The Government Of The United States, As Represented By The Secretary Of The Army Uso de mejoradores para penetracion de la piel y agentes de alteracion de barrera para mejorar la respuesta inmune transcutanea.
US6646068B2 (en) * 1998-03-12 2003-11-11 Lucite International Uk Limited Polymer composition
WO1999051259A2 (en) * 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
ATE331739T1 (de) 1998-04-28 2006-07-15 Inex Pharmaceuticals Corp Polyanionische polymere mit verbesserter fusogenfähigkeit
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
NZ508650A (en) * 1998-05-14 2003-05-30 Coley Pharm Gmbh Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US6881561B1 (en) 1998-05-27 2005-04-19 Cheil Jedang Corporation Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
EP1089764B1 (de) 1998-06-10 2004-09-01 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Stimulierung des immunsystems
WO1999066947A1 (en) * 1998-06-23 1999-12-29 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant therapy
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
CA2335393C (en) 1998-07-20 2008-09-23 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
EP1100807A1 (de) 1998-07-27 2001-05-23 University Of Iowa Research Foundation Stereoisomere von cpg oligonukleotiden und verwandte verfahren
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP0979869A1 (de) 1998-08-07 2000-02-16 Hoechst Marion Roussel Deutschland GmbH Kurze Oligonukleotide zur Hemmung von VEGF-Expression
US7049302B1 (en) * 1998-08-10 2006-05-23 Antigenics Inc. Compositions of CPG and saponin adjuvants and uses thereof
US20010034330A1 (en) 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
DE69943392D1 (de) * 1998-08-20 2011-06-09 Du Pont Gene für fettsäuremodfizierende enzyme von planzen und damit verbundene bildung von konjugierten doppelbindungen
EP1108017A2 (de) 1998-09-03 2001-06-20 Coley Pharmaceutical GmbH Oligonukleotide mit einem g-motif und deren verwendungen
US20020065236A1 (en) 1998-09-09 2002-05-30 Yew Nelson S. CpG reduced plasmids and viral vectors
FR2783170B1 (fr) 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
EP1671646A3 (de) 1998-09-18 2007-08-29 Dynavax Technologies Corporation Verfahren zur Behandlung von IgE- assoziierten Krankheiten und Zusammensetzungen zur Verwendung in diesen Verfahren
CA2343052A1 (en) 1998-09-18 2000-03-30 Dynavax Technologies Corporation Methods of treating ige-associated disorders and compositions for use therein
WO2000020039A1 (en) 1998-10-05 2000-04-13 The Regents Of The University Of California Methods and adjuvants for stimulating mucosal immunity
AU6425999A (en) 1998-10-09 2000-05-01 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP1165773A4 (de) 1999-02-02 2005-01-05 Biocache Pharmaceuticals Inc VERBESSERTE ANTIGEN-PRäSENTATION
US6887464B1 (en) * 1999-02-02 2005-05-03 Biocache Pharmaceuticals, Inc. Advanced antigen presentation platform
JP2002536344A (ja) 1999-02-05 2002-10-29 ジエンザイム コーポレイション 抗腫瘍免疫を発生させるためのカチオン性脂質の使用
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
WO2000054803A2 (en) * 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
SI1163000T1 (sl) 1999-03-19 2008-06-30 Glaxosmithkline Biolog Sa Vakcina proti antigenom iz bakterij
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US6625426B2 (en) * 1999-03-22 2003-09-23 Ronald Baratono Combined rear view mirror and telephone
EP1176966B1 (de) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU4642600A (en) 1999-04-15 2000-11-02 Regents Of The University Of California, The Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells
PL203951B1 (pl) 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU4978100A (en) 1999-04-29 2000-11-17 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers
AP1891A (en) 1999-05-06 2008-09-23 The Immune Response Corp HIV immunogenic compositions and methods.
US6737066B1 (en) * 1999-05-06 2004-05-18 The Immune Response Corporation HIV immunogenic compositions and methods
AU776268B2 (en) 1999-06-08 2004-09-02 Aventis Pasteur Immunostimulant oligonucleotide
US6479504B1 (en) 1999-06-16 2002-11-12 The University Of Iowa Research Foundation Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
ATE306938T1 (de) 1999-06-29 2005-11-15 Glaxosmithkline Biolog Sa Verwendung von cpg als adjuvans für hivimpstoff
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB9915204D0 (en) 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
FR2795963A1 (fr) * 1999-07-08 2001-01-12 Pasteur Merieux Serums Vacc Polynucleotide immunostimulant
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
WO2001012804A2 (en) 1999-08-13 2001-02-22 Hybridon, Inc. MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
EP1204425B1 (de) 1999-08-19 2009-01-07 Dynavax Technologies Corporation Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
US20050249794A1 (en) 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
US6395678B1 (en) * 1999-09-01 2002-05-28 Aero-Terra-Aqua Technologies Corporation Bead and process for removing dissolved metal contaminants
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
AP2006003503A0 (en) * 1999-09-25 2006-02-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EP1220684B2 (de) * 1999-09-27 2010-07-14 Coley Pharmaceutical Group, Inc. Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
US20070031446A1 (en) 2003-07-11 2007-02-08 Intercell Ag Hcv vaccines
JP2003512826A (ja) * 1999-10-27 2003-04-08 カイロン コーポレイション Ｈｃｖ特異的ｔ細胞の活性化
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
NZ518999A (en) 1999-11-19 2002-12-20 Csl Ltd Vaccine compositions
US20010031262A1 (en) * 1999-12-06 2001-10-18 Michael Caplan Controlled delivery of antigens
AU2593701A (en) 1999-12-21 2001-07-03 Regents Of The University Of California, The Method for preventing an anaphylactic reaction
AU781812B2 (en) 2000-01-13 2005-06-16 Antigenics, Inc. Innate immunity-stimulating compositions of CPG and saponin and methods thereof
EP1322655B1 (de) * 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
AU3108001A (en) * 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US6815429B2 (en) 2000-01-26 2004-11-09 Hybridon, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
MXPA02007413A (es) 2000-01-31 2004-07-30 Smithkline Beecham Biolog Vacuna para la inmunizacion profilactica o terapeutica contra el vih.
US6552006B2 (en) * 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
FR2805265B1 (fr) 2000-02-18 2002-04-12 Aventis Pasteur Oligonucleotides immunostimulants
US20030130217A1 (en) * 2000-02-23 2003-07-10 Eyal Raz Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US6613751B2 (en) * 2000-02-23 2003-09-02 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US6423539B2 (en) 2000-02-24 2002-07-23 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant treatment by in vivo activation of dendritic cells
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US6851845B2 (en) * 2000-03-10 2005-02-08 The Maitland Company, Inc. Method and apparatus for processing waste material
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
AU2001249609A1 (en) 2000-03-28 2001-10-08 Department Of Veterans Affairs Methods for increasing a cytotoxic T lymphocyte response in vivo
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
AU2001251407A1 (en) 2000-04-07 2001-10-23 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
US7524826B2 (en) 2000-04-14 2009-04-28 Mcmaster University And Hamilton Health Sciences Corporation Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque
US6321873B1 (en) * 2000-04-21 2001-11-27 Tra-Lor-Mate, Inc. Ladder mounting system
ES2238044T3 (es) 2000-05-01 2005-08-16 Hybridon, Inc. Modulacion de la estimulacion inmunologica mediada por el oligonucleotido cpg mediante modificacion posicional de nucleosidos.
WO2001085910A2 (en) * 2000-05-05 2001-11-15 The Regents Of The University Of California Agents that modulate dna-pk activity and methods of use thereof
US20020013287A1 (en) 2000-05-09 2002-01-31 Reliable Biopharmaceuticals, Inc. St Louis Missouri Polymeric compounds useful as prodrugs
ATE299696T1 (de) 2000-05-12 2005-08-15 Pharmacia & Upjohn Co Llc Impfstoffzusammensetzung und verfahren zur herstellung derselben sowie verfahren zur impfung von wirbeltieren
US6339630B1 (en) * 2000-05-18 2002-01-15 The United States Of America As Represented By The United States Department Of Energy Sealed drive screw operator
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
AU2001275294A1 (en) * 2000-06-07 2001-12-17 Biosynexus Incorporated. Immunostimulatory RNA/DNA hybrid molecules
AU7013401A (en) * 2000-06-22 2002-01-02 Univ Iowa Res Found Methods for enhancing antibody-induced cell lysis and treating cancer
US20020165178A1 (en) * 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
BRPI0112928B1 (pt) 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
WO2002009748A1 (en) 2000-07-31 2002-02-07 Yale University Innate immune system-directed vaccines
US20020198165A1 (en) * 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
CA2420840A1 (en) 2000-09-01 2003-02-27 Epigenomics Ag Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3'
WO2002018631A2 (de) * 2000-09-01 2002-03-07 Epigenomics Ag Diagnose von bestehenden erkrankungen oder der prädisposition für bestimmte erkrankungen
US20020091097A1 (en) * 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
WO2002022809A2 (en) * 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US6787524B2 (en) * 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
CA2423487C (en) 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
SE0003538D0 (sv) * 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
US7537772B1 (en) * 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
FR2814958B1 (fr) 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
KR100831139B1 (ko) * 2000-10-18 2008-05-20 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP1330520A2 (de) 2000-11-02 2003-07-30 Inex Pharmaceuticals Corp. Therapeutische oligonukleotide mit reduzierter toxizität
EP1360486A2 (de) * 2000-12-08 2003-11-12 3M Innovative Properties Company Screeningverfahren zur identifizierung von selektiven interferon-alpha-induzierenden verbindungen
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US20030055014A1 (en) * 2000-12-14 2003-03-20 Bratzler Robert L. Inhibition of angiogenesis by nucleic acids
DE60142410D1 (de) * 2000-12-27 2010-07-29 Dynavax Tech Corp Immunomodulatorische polynukleotide und verfahren zur deren verwendung
US7337306B2 (en) * 2000-12-29 2008-02-26 Stmicroelectronics, Inc. Executing conditional branch instructions in a data processor having a clustered architecture
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7176296B2 (en) 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US20030129605A1 (en) 2001-05-04 2003-07-10 Dong Yu Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosophonate linkages
EP1528937B1 (de) * 2001-06-05 2016-08-10 The Regents Of The University Of Michigan Nanoemulsionsvakzine
EP1395262A4 (de) 2001-06-15 2006-04-12 Ribapharm Corp Nucleosid-vakzine-adjuvantien
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US20040132677A1 (en) 2001-06-21 2004-07-08 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same-IV
CN100334228C (zh) 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
WO2003000232A2 (en) 2001-06-25 2003-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides
US20030003970A1 (en) 2001-06-28 2003-01-02 Alan Johnson Portable communications device
CN1931365A (zh) 2001-06-29 2007-03-21 希龙公司 Hcv e1e2疫苗组合物
US6982033B2 (en) * 2001-07-13 2006-01-03 Donald Hubbard H Aerobic treatment plant with filter pipe
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003040308A2 (en) 2001-07-27 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo
WO2003012061A2 (en) * 2001-08-01 2003-02-13 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
WO2003014316A2 (en) * 2001-08-07 2003-02-20 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
JP2005510462A (ja) 2001-08-10 2005-04-21 ダイナバックス テクノロジーズ コーポレイション 免疫調節オリゴヌクレオチドの生成及びその使用方法
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
SI1446162T1 (sl) * 2001-08-17 2009-04-30 Coley Pharm Gmbh Kombinacija zaporedja imunostimulatornih oligonukleotidov z izboljšano aktivnostjo
US20030133913A1 (en) 2001-08-30 2003-07-17 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
WO2003027313A2 (en) * 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US7514415B2 (en) * 2002-08-01 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
DE60234782D1 (de) 2001-09-28 2010-01-28 Purdue Research Foundation Behandlungsverfahren mit liganden-immunogenkonjugaten
CA2461315A1 (en) * 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
CN100438908C (zh) 2001-10-06 2008-12-03 梅瑞尔有限公司 CpG制剂及相关方法
DK1455593T3 (da) 2001-10-06 2013-08-26 Merial Ltd Fremgangsmåder og sammensætninger til fremme af vækst og medfødt immunitet hos unge dyr
AU2002360278A1 (en) * 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US20030125292A1 (en) 2001-11-07 2003-07-03 Sean Semple Mucoscal vaccine and methods for using the same
DK1719511T3 (da) 2001-11-16 2009-04-14 Coley Pharm Group Inc N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
CA2469082A1 (en) * 2001-12-04 2003-06-12 Raj K. Puri Chimeric molecule for the treatment of th2-like cytokine mediated disorders
DE10161755B4 (de) * 2001-12-15 2005-12-15 Infineon Technologies Ag Kontaktstift zum Testen mikroelektronischer Bauteile mit kugelförmigen Kontakten
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) * 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
WO2003055514A1 (en) 2001-12-21 2003-07-10 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
CA2474709A1 (en) 2002-02-04 2003-08-14 Biomira, Inc. Immunostimulatory, covalently lipidated oligonucleotides
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20030232443A1 (en) 2002-06-18 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of centromere protein B expression
US8153141B2 (en) * 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
WO2003087308A2 (en) * 2002-04-11 2003-10-23 Zymogenetics, Inc. Use of interleukin-24 to treat ovarian cancer
CA2483012C (en) * 2002-04-22 2011-05-24 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
US6948271B2 (en) * 2002-05-06 2005-09-27 Innovative Supply, Inc. Identification and tracking system for deceased bodies
BR0309814A (pt) * 2002-05-08 2005-03-01 Dana Corp Métodos de formação de plasma
JP2005532315A (ja) 2002-05-10 2005-10-27 イネックス ファーマシューティカルズ コーポレイション メチル化免疫刺激性オリゴヌクレオチド及びその使用方法
EP1505942B1 (de) 2002-05-10 2008-08-13 Tekmira Pharmaceuticals Corporation Pathogene impstoffe und verfahren zur deren verwendung
US20040009944A1 (en) 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
CA2487452A1 (en) 2002-05-28 2003-12-04 Robinson Ramirez-Pineda A method for generating antigen-presenting cells
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
US20040013688A1 (en) * 2002-07-03 2004-01-22 Cambridge Scientific, Inc. Vaccines to induce mucosal immunity
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AU2003255969A1 (en) 2002-07-17 2004-02-02 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease
CN1468957A (zh) 2002-07-19 2004-01-21 中国人民解放军第二军医大学 一种用作人用治疗性疫苗佐剂的质粒
US20050209183A1 (en) 2002-07-25 2005-09-22 Phenion Gmbh & Co. Kg Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated CPG motifs
EP1393745A1 (de) 2002-07-29 2004-03-03 Hybridon, Inc. Modulierung der immunstimulierenden Eigenschaften von Oligonukleotiden und Analoga durch optimale Darstellung der 5'-Enden
NZ538628A (en) * 2002-08-12 2008-06-30 Dynavax Tech Corp Immunomodulatory compositions, methods of making, and methods of use thereof
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US6928476B2 (en) * 2002-08-23 2005-08-09 Mirra, Inc. Peer to peer remote data storage and collaboration
US6744084B2 (en) * 2002-08-29 2004-06-01 Micro Technology, Inc. Two-transistor pixel with buried reset channel and method of formation
US7186700B2 (en) * 2002-09-13 2007-03-06 Idenix Pharmaceuticals, Inc. β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US6994870B2 (en) * 2002-09-18 2006-02-07 Jaw-Ji Tsai Local nasal immunotherapy with allergen strip for allergic rhinitis
AU2003278845A1 (en) 2002-09-19 2004-04-08 Coley Pharmaceutical Gmbh Toll-like receptor 9 (tlr9) from various mammalian species
US6988995B2 (en) * 2002-09-30 2006-01-24 Carl Zeiss Meditec, Inc. Method and system for detecting the effects of Alzheimer's disease in the human retina
US8043622B2 (en) * 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
JP4976653B2 (ja) * 2002-11-01 2012-07-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス 免疫刺激性ＣｐＧオリゴヌクレオチドを用いてバイオテロ病原体による感染症を予防する方法
WO2004041183A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of California Methods of treating pulmonary fibrotic disorders
AU2003300919A1 (en) * 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
KR100525321B1 (ko) 2002-12-13 2005-11-02 안웅식 파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
CN100546998C (zh) 2002-12-23 2009-10-07 戴纳伐克斯技术股份有限公司 免疫刺激序列寡核苷酸和使用方法
JP2006516099A (ja) 2002-12-23 2006-06-22 ダイナバックス テクノロジーズ コーポレイション 分枝状の免疫調節化合物及び該化合物の使用方法
US7851453B2 (en) 2003-01-16 2010-12-14 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7189781B2 (en) * 2003-03-13 2007-03-13 H.B. Fuller Licensing & Finance Inc. Moisture curable, radiation curable sealant composition
CN100355453C (zh) 2003-03-24 2007-12-19 英特塞尔股份公司 改进的疫苗
CA2517839A1 (en) 2003-03-26 2004-10-07 Martin F. Bachmann Melan-a peptide analogue-virus-like-particle conjugates
US20040235770A1 (en) 2003-04-02 2004-11-25 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
EP1631687A2 (de) 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Verfahren und produkte zur identifizierung und beurteilung von tlr-liganden
JP3887346B2 (ja) * 2003-04-28 2007-02-28 株式会社東芝 映像信号処理装置及び映像信号処理方法、映像表示装置
AU2004241093B2 (en) 2003-05-16 2009-08-27 Idera Pharmaceuticals, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
EP1484336A1 (de) * 2003-06-02 2004-12-08 Pevion Biotech Ltd. Methode zur Herstellung von konformationseingeschränkten Peptiden, Peptidomimetika und deren Verwendung als synthetische Vaccine
EP2371834B1 (de) 2003-06-11 2016-02-17 Idera Pharmaceuticals, Inc. Stabilisierte Oligonukleotide als Immunmodulatoren
JPWO2004110489A1 (ja) * 2003-06-13 2006-07-20 第一アスビオファーマ株式会社 Ｔｈ１型免疫疾患予防又は治療用医薬組成物
EP2356999A1 (de) * 2003-06-17 2011-08-17 Mannkind Corporation Zusammensetzung zur auslösung, verbesserung und erhaltung von Immunantworten gegen MHC klasse -I-beschränkte Epitope, für prophylaktische oder therapeutische zwecke
JP2007524615A (ja) * 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
US20040265833A1 (en) 2003-06-23 2004-12-30 Cathy Lofton-Day Methods and nucleic acids for the analysis of colorectal cell proliferative disorders
KR20060031607A (ko) 2003-07-10 2006-04-12 사이토스 바이오테크놀로지 아게 패킹된 바이러스-양 입자
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2004259204B2 (en) 2003-07-15 2010-08-19 Idera Pharmaceuticals, Inc. Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
CA2544240A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
WO2005021726A2 (en) 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic hiv compositions and related methods
US7576068B2 (en) * 2003-09-05 2009-08-18 Anadys Pharmaceuticals, Inc. Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
EP1671643A1 (de) 2003-09-08 2006-06-21 Intellectual Property Consulting Inc. Medizinische zusammensetzung zur behandlung der chronischen hepatitis c
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2005027920A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
WO2005034979A2 (en) 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
US20050087538A1 (en) * 2003-10-23 2005-04-28 Wolfe Darrell R. Iceless multiple can cooler
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
CA2540949A1 (en) 2003-10-30 2005-05-12 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
JP4088246B2 (ja) * 2003-12-05 2008-05-21 富士通株式会社 リングネットワークのマスタ設定方法及び装置
WO2005060377A2 (en) 2003-12-08 2005-07-07 Hybridon, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
US20070172315A1 (en) * 2003-12-18 2007-07-26 Barrett Robert K Method and Apparatus for Creating Soil or Rock Subsurface Support
EP1550458A1 (de) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergisitische liposomale Adjuvantien
KR100558851B1 (ko) 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
AU2005213460A1 (en) * 2004-02-06 2005-08-25 Mayo Foundation For Medical Education And Research Complexed polypeptide and adjuvant for improved vaccines
US20050181035A1 (en) 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
EP1720568A2 (de) 2004-02-19 2006-11-15 Coley Pharmaceutical Group, Inc. Immunstimulatorische virale rna-oligonucleotide
CN1918293A (zh) 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
AU2005222909B2 (en) 2004-03-12 2010-03-11 Idera Pharmaceuticals, Inc. Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
EP1730281A2 (de) * 2004-04-02 2006-12-13 Coley Pharmaceutical Group, Inc. Immunstimulierende nukleinsäuren zur induzierung von il-10-antworten
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
WO2005115449A1 (en) * 2004-05-28 2005-12-08 Alk-Abelló A/S Method of treating allergy and infection by eliciting an iga antibody response
US8399025B2 (en) * 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
AU2005326144A1 (en) 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
US7756043B1 (en) * 2004-06-09 2010-07-13 Sprint Communications Company L.P. Method for identifying high traffic origin-destination node pairs in a packet based network
US7427405B2 (en) 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
EP2901856B1 (de) 2004-06-15 2017-08-09 Idera Pharmaceuticals, Inc. Immunstimulatorische Oligonukleotidmultimere
US8175282B2 (en) * 2004-06-25 2012-05-08 The Tc Group A/S Method of evaluating perception intensity of an audio signal and a method of controlling an input audio signal on the basis of the evaluation
US7534449B2 (en) * 2004-07-01 2009-05-19 Yale University Targeted and high density drug loaded polymeric materials
EP1781325A2 (de) 2004-07-18 2007-05-09 CSL Limited Immunstimulierender komplex und oligonucleotidformulierungen zur induzierung verbesserter interferon-gamma-antworten
CA2574090A1 (en) * 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
US20060058261A1 (en) * 2004-09-15 2006-03-16 Andre Aube Chitin derivatives for hyperlipidemia
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
KR100721928B1 (ko) * 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
US20060105979A1 (en) 2004-11-08 2006-05-18 Hybridon, Inc. Synergistic inhibition of VEGF and modulation of the immune response
US20060171968A1 (en) 2005-01-07 2006-08-03 Alk-Abello A/S Method of preventive treatment of allergy by oromucosal administration of an allergy vaccine
WO2007042554A2 (en) * 2005-10-12 2007-04-19 Cancer Research Technology Ltd. Methods and compositions for treating immune disorders
CN101160401A (zh) * 2005-02-24 2008-04-09 科勒制药集团公司 免疫刺激寡核苷酸
EP1874325A2 (de) 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Verfahren zur behandlung von durch infektionserkrankungen verschlimmertes asthma
US20060241076A1 (en) 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US7325152B2 (en) * 2005-06-30 2008-01-29 Infineon Technologies Ag Synchronous signal generator
NZ565311A (en) * 2005-07-07 2009-10-30 Pfizer Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
CA2620582C (en) * 2005-08-31 2015-11-10 Dennis M. Klinman Methods of altering an immune response induced by cpg oligodeoxynucleotides
EA013375B1 (ru) 2005-09-16 2010-04-30 Коли Фармасьютикал Гмбх МОДУЛЯЦИЯ ИММУНОСТИМУЛИРУЮЩИХ СВОЙСТВ КОРОТКОЙ ИНТЕРФЕРИРУЮЩЕЙ РИБОНУКЛЕИНОВОЙ КИСЛОТЫ (siРНК) С ПОМОЩЬЮ МОДИФИКАЦИИ НУКЛЕОТИДОВ
WO2007088423A2 (en) 2005-09-16 2007-08-09 Coley Pharmaceutical Gmbh Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
BRPI0616770A2 (pt) 2005-09-27 2011-06-28 Coley Pharm Gmbh modulação de respostas imunes mediadas por tlr empregando oligonucleotìdeos adaptadores
US20070093439A1 (en) 2005-10-25 2007-04-26 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
US20070243209A1 (en) * 2005-10-28 2007-10-18 Health Research, Inc. Compositions and methods for prevention and treatment of fungal diseases
AU2006306805A1 (en) * 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
CA2628328A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
US7776834B2 (en) 2005-11-07 2010-08-17 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP2371956A3 (de) 2005-11-07 2012-01-04 Idera Pharmaceuticals Immunostimulatorische Eigenschaften von Oligonukleotid-basierten Verbindungen mit modifizierten immunostimulatorischen Dinukleotiden
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
CA2630118A1 (en) 2005-11-07 2007-05-18 Sudhir Agrawal Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
DK1957647T3 (en) * 2005-11-25 2015-04-07 Zoetis Belgium S A Immunostimulatory oligoribonucleotides
JP2009521218A (ja) 2005-12-20 2009-06-04 イデラ ファーマシューティカルズ インコーポレイテッド 異なる長さのパリンドロームセグメントを含むパリンドローム免疫調節オリゴヌクレオチド（ｉｍｏ（ｔｍ））の免疫賦活作用
EP2405002B1 (de) * 2006-02-15 2014-09-24 AdiuTide Pharmaceuticals GmbH Zusammensetzungen und Verfahren für Oligonucleotidformulierungen
DE102006007433A1 (de) 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
WO2008019018A2 (en) * 2006-08-03 2008-02-14 William Soo Hoo Bioactive molecular matrix and methods of use in the treatment of disease
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
EP2056880A4 (de) * 2006-08-16 2010-10-13 Protiva Biotherapeutics Inc Nukleinsäuremodulation der durch den toll-artigen rezeptor vermittelten immunstimulation
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008033432A2 (en) 2006-09-12 2008-03-20 Coley Pharmaceutical Group, Inc. Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2486938B1 (de) * 2006-09-26 2018-05-09 Infectious Disease Research Institute Impfstoffzusammensetzung mit einem synthetischen Adjuvans
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
MX2009003403A (es) 2006-09-27 2009-04-09 Coley Pharm Group Inc Composiciones de ligandos de tlr y antivirales.
RU2009115687A (ru) * 2006-10-26 2010-11-10 Коли Фармасьютикал Гмбх (De) Олигорибонуклеотиды и их применения
US20090142362A1 (en) * 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
AU2007329375A1 (en) * 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
US8057804B2 (en) * 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
JP6144448B2 (ja) * 2006-12-28 2017-06-07 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 単純ヘルペスウイルス複合サブユニットワクチンおよびその使用方法
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
US20100285041A1 (en) 2007-05-17 2010-11-11 Eugen Uhlmann Class A Oligonucleotides with Immunostimulatory Potency
WO2009022215A1 (en) * 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
KR20100075843A (ko) * 2007-08-21 2010-07-05 다이나박스 테크놀로지 코퍼레이션 인플루엔자 단백질 조성물 및 그 제조 및 사용 방법
WO2009027105A2 (en) * 2007-08-31 2009-03-05 Neurimmune Therapeutics Ag Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
US7892567B2 (en) * 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease
KR20100068422A (ko) 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
TW200932274A (en) * 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof
US7720322B2 (en) * 2008-06-30 2010-05-18 Intuitive Surgical, Inc. Fiber optic shape sensor
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
US8053422B2 (en) * 2008-12-04 2011-11-08 The United States Of America As Represented By The Department Of Health And Human Services Anti-cancer oligodeoxynucleotides

Also Published As

Publication number Publication date
EP0948510A4 (de) 2000-08-02
US8158592B2 (en) 2012-04-17
US20050070491A1 (en) 2005-03-31
EP1746159A2 (de) 2007-01-24
US20050049216A1 (en) 2005-03-03
US20050123523A1 (en) 2005-06-09
US20060003955A1 (en) 2006-01-05
AU5242498A (en) 1998-05-22
US20060089326A1 (en) 2006-04-27
US7517861B2 (en) 2009-04-14
US8058249B2 (en) 2011-11-15
EP1714969A2 (de) 2006-10-25
US20040198688A1 (en) 2004-10-07
JP2004041224A (ja) 2004-02-12
US7402572B2 (en) 2008-07-22
JP2010150280A (ja) 2010-07-08
JP5082063B2 (ja) 2012-11-28
US20070078104A1 (en) 2007-04-05
US8129351B2 (en) 2012-03-06
JP2001503267A (ja) 2001-03-13
CN101265285A (zh) 2008-09-17
CN1235609A (zh) 1999-11-17
US7888327B2 (en) 2011-02-15
US20050148537A1 (en) 2005-07-07
US20040229835A1 (en) 2004-11-18
US20050277604A1 (en) 2005-12-15
US20050277609A1 (en) 2005-12-15
US20050004061A1 (en) 2005-01-06
JP2008289495A (ja) 2008-12-04
AU9724901A (en) 2002-02-07
NZ335397A (en) 2000-11-24
ATE332966T1 (de) 2006-08-15
KR20000052994A (ko) 2000-08-25
US20080031936A1 (en) 2008-02-07
US7674777B2 (en) 2010-03-09
AU775185B2 (en) 2004-07-22
EP0948510A1 (de) 1999-10-13
EP0948510B1 (de) 2006-07-12
US20050267064A1 (en) 2005-12-01
US20050049215A1 (en) 2005-03-03
PT948510E (pt) 2006-12-29
EP2360252B8 (de) 2017-04-12
AU2004218696A1 (en) 2004-11-04
US20050054602A1 (en) 2005-03-10
US20080026011A1 (en) 2008-01-31
US20030050261A1 (en) 2003-03-13
CA2270345C (en) 2014-05-13
US20050215500A1 (en) 2005-09-29
EP1746159A3 (de) 2009-11-25
WO1998018810A1 (en) 1998-05-07
JP2003286174A (ja) 2003-10-07
US20050059625A1 (en) 2005-03-17
EP2360252A1 (de) 2011-08-24
EP2360252B1 (de) 2017-02-08
US20100125101A1 (en) 2010-05-20
CN100338086C (zh) 2007-09-19
EP1714969A3 (de) 2010-03-03
US20040132685A1 (en) 2004-07-08
US20050233995A1 (en) 2005-10-20
US7879810B2 (en) 2011-02-01
US20050032736A1 (en) 2005-02-10
CA2270345A1 (en) 1998-05-07
US20050239732A1 (en) 2005-10-27
EP2322615A1 (de) 2011-05-18
US7723500B2 (en) 2010-05-25
US20040167089A1 (en) 2004-08-26
ES2624859T3 (es) 2017-07-17
ES2268736T3 (es) 2007-03-16
US8258106B2 (en) 2012-09-04
US6207646B1 (en) 2001-03-27
US20070066553A1 (en) 2007-03-22
US20090202575A1 (en) 2009-08-13
DK0948510T3 (da) 2006-10-30
US20050171047A1 (en) 2005-08-04
KR100689942B1 (ko) 2007-03-09
US20040147468A1 (en) 2004-07-29
US20050233999A1 (en) 2005-10-20
DE69736331T2 (de) 2007-08-09
AU2004218696B2 (en) 2008-11-06
US7723022B2 (en) 2010-05-25

Similar Documents

Publication Publication Date Title
DE69736331D1 (de) Immunstimulierende nukleinsaeuremolekuele
EP1167377A3 (de) Immunomodulatorische Oligonukleotide
BG106538A (en) Immunostimulatory nucleic acids
BR9814483A (pt) "vacina"
EP1985702A3 (de) CPG-ähnliche Nukleinsäuren und Verwendungsverfahren dafür
MXPA02012010A (es) Oligodesoxinucleotidos inmunoestimulantes.
ATE190981T1 (de) 2'-modifizierte nukleotide
DE60221004D1 (de) Immunostimulierende oligodeoxyribonuklein moleküle
ZA200006765B (en) Methods and products for inducing mucosal immunity.
EP2028274A3 (de) Ein Antisense Oligonukleotid gegen das TGF-beta2 Gen
AU1534795A (en) Modified oligonucleotides
ATE263181T1 (de) Chemische synthese von 6-o-alkyl erythromycin a
AU2002242900A1 (en) Conjugated homo-and copolymers comprising substituted or unsubstituted heteroaryl group, its preparation and uses
DK0725821T3 (da) Nucleinsyremarkørstige til estimering af masse
IT1231284B (it) Apparecchiatura per il condizionamento dell'aria, a duplice possibilita' di funzionamento.
ATA87389A (de) Geblaesebrenner, insbesondere sturzbrenner
AU2001258274A1 (en) Synthetic oligonucleotides as inducers of erythroid differentiation
FR2680797B1 (de)
UA9689A (uk) Індуктор інтерферону першого типу в організмі людини та тварин
IT8907091V0 (it) Diffusore per generatori di un flusso d'aria, segnatamente per apparecchi asciugacapelli
IT236073Y1 (it) Diffusore di aria per aerazione.
IT212844Z2 (it) Separatore d'aria di linea per impianti di riscaldamento.

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: WEINER, GEORGE, IOWA CITY, IA 52246, US

Inventor name: STEINBERG, ALFRED D., POTOMAC, MD 20854, US

Inventor name: KLINMAN, DENNIS, POTOMAC, MD 20854, US

Inventor name: KLINE, N., JOEL, IOWA CITY, IA 52242, US

Inventor name: KRIEG, ARTHUR M., WELLESLEY, MASS., US

8363 Opposition against the patent
8331 Complete revocation